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ANTHELMINTIC AGENT IN ALPACAS AND LLAMAS
WITH THEORETICAL APPLICATIONS
CHAPTER 1
INTRODUCTION
The primary goal of pharmacokinetics is to generate the mathematical parameters
that quantitate physiological processes as an aid to better understand a drug's disposition in
the body. Based on the parameters obtained, the proper dosage regimen for each animal
species can be determined.
Information of pharmacokinetic of antimicrobials in alpacas is very limited so the
appropriate dosage regimen of antimicrobials in alpacas has not been defined yet. Drug
dosing for the treatment of bacterial infections in alpacas are frequently based on dosing
used in ruminants.
Chapter 2 presents the pharmacokinetics of oxytetracycline which is a widely used
broad spectrum antibiotic in veterinary medicine. The objective of this study is to
investigate the pharmacokinetics of oxytetracycline in alpacas following intravenous and
intramuscular administrations. The study was conducted in six healthy alpacas following a
single administration of an intravenous injection of a solution of oxytetracycline and an
intramuscular injection of a sustained action product of oxytetracycline at a dose of 10
mg/kg body weight. Both compartmental and noncompartmental analyses were performed
to determine the pharmacokinetic parameters. In order to evaluate the absorption process
that occurs after intramuscular injection of the sustained action oxytetracycline product,
deconvolution and Loo-Riegelman approaches were utilized. The proper dosage regimens
were proposed based on the pharmacokinetic parameters obtained in conjunction with the
minimum inhibitory concentration of oxytetracycline against commonly known pathogens.2
Chapter 3 contrasts the pharmacokinetics of oxytetracycline in alpacas to llamas
following intravenous and intramuscular administration at a single dose of 10 mg/kg. The
pharmacokinetic parameters obtained from chapter 2 were compared to the results
previously obtained in llamas and determined if the two animals handle oxytetracycline in
the same manner.
Chapter 4 presents the pharmacokinetics of florfenicol in alpacas following
intravenous administration of a single dose of 20 mg/kg. The study was carried out on six
healthy alpacas after intravenous administration. Both compartmental and
noncompartmental analyses were performed to determine the pharmacokinetic parameters.
The proper dosage regimen for florfenicol in alpacas was proposed based on the
pharmacokinetic parameters obtained to maintain the minimum inhibitory of florfenicol
against pathogenic bacteria.
Chapter 5 is the comparison of pharmacokinetic parameters of florfenicol in
alpacas with the results previously obtained in llamas and determines if the disposition
kinetics of florfenicol in these two animals is similar.
Chapter 6 presents the pharmacokinetics of clorsulon which is a narrow-spectrum
anthelmintic agent. Clorsulon was approved by the US Food and Drug Administration for
the treatment of liver flukes in cattle at the recommended dose of 7 mg/kg. The
preliminary efficacy study of clorsulon in llamas showed that clorsulon at the
recommended dose was not effective against liver flukes. This clorsulon pharmacokinetic
study was conducted in five healthy llamas following oral administration at a single dose
of 14 mg/kg. Both compartmental and noncompartmental analyses were performed to
determine the pharmacokinetic parameters.
Chapter 7 presents the evaluation of preliminary AUC equations of drugs
following one-compartment system with first-order input and two-compartment system
after IV administration with nonlinear elimination kinetics. The plasma concentration-time
curves of drugs following these models were generated using the fourth-order Runge-Kutta
method. The AUC value calculated from the preliminary equations were compared to the
value calculated using trapezoidal rule method.CHAPTER 2
PHARMACOKINETICS OF OXYTETRACYCLINE IN ALPACAS AFTER
INTRAVENOUS AND LONG-ACTING INTRAMUSCULAR
ADMINISTRATION
Triporn Wattananat, J. Mark Christensen, and Bradford B. SmithEl
ABSTRACT
Oxytetracycline is a widely used broad spectrum antibiotic for the treatment of
various infections in veterinary medicine. The purpose of this study was to investigate the
pharmacokinetics of oxytetracycline in alpacas following intravenous and intramuscular
administration at a single dose of oxytetracycline at a dosage of 10 mg/kg body weight.
After the IV dose, the plasma concentration-time curves were best fitted to a three-
compartment open model. The apparent volume of distribution of the central compartment
(Vc) was 0.16 ± 0.05 L/kg, while the volume of distribution at steady state (Vss) was 1.24
± 0.16 L/kg. The harmonic mean elimination half-life was 8.88 ± 1.43 hours. The total
body clearance was 0.13 ± 0.02 L/kg/h. After IM administration, a two-compartment open
model with two parallel first-order input functions best described the plasma concentration-
time profiles. The rapid absorption rate constant was 0.36 ± 017mm1(21.5 ± 10.0 h')
while the slow absorption rate constant was 0.0003 ± 0.0001 mm' (0.0 16 ± 0.003 h').
According to the pharmacokinetic parameters obtained, the proper dosage regimen for
alpacas is 8 mg/kg every 12 hours with IV injection and an initial loading dose of 20 mg/kg
and a maintenance dose of 10 mg/kg every 48 hours with LA-IM formulation will achieve
a trough concentration of 2.26 and 3.04 jig/mL, respectively, at steady state. These dosing
schedules will allow plasma concentrations above the MIC of 2 jig/mL for most
microorganisms.INTRODUCTION
Various bacterial infections in alpacas have been reported in the literature. Those
diseases include Alpaca fever, anthrax, brucellosis, blackleg, botryomycosis, John's
disease, meningoencephalitis, etc., as shown in Table 2.1 (Thedford and Johnson, 1989;
Fowler, 1998).
Tetracycline was discovered during the systematic screening of microorganisms
obtained from soil specimens for antimicrobial properties. The tetracycline group of
antibiotic includes chiortetracycline and oxytetracycline which are naturally produced by
Streptomyces aureofaciens and Streptoinyces rirnosus, respectively, whereas doxycycline,
minocycline, methacycline, tetracycline, rolitetracycline, and demeclocycline are
semisynthetic derivatives (Hardman and Limbird, 1999). The hydronaphthacene nucleus
containing four fused 6-membered rings forms the basic structure from which the various
tetracyclines are made. Their structural formulas are shown in Figure 2.1 and Table 2.2.
Tetracycline antibiotics have a broad spectrum of activity against aerobic and
anaerobic gram positive and gram negative bacteria, including Rickettsia, Coxiella
burn etii, Mycoplasina pneuinoniae, Haernoph i/us influenzae, Chlarnydia, Staphylococcus
aureus, Bacillus anthraces, and Neisseria spp. The lipophilic congeners, minocycline and
doxycycline are more active than the hydrophilic ones such as oxytetracycline,
tetracycline, and demeclocycline (Lambert and O'Grady, 1992).
The bacteriostatic action of tetracyclines is due to their ability to inhibit bacterial
protein synthesis. By binding to the 30S ribosomal subunit, tetracyclines prevent access of
t-RNA to the acceptor (A) site on the m-RNA ribosome complex, so that the elongation of
the amino acid chain during protein synthesis in bacteria is terminated (Hardman and
Limbird, 1999). This bacteriostatic effect of tetracycline becomes cidal at extremely high
concentrations (Bush ci al., 2000).
Tetracyclines are generally regarded as relatively safe, but they produce a fairly
large number of adverse effects which may be related to their severely irritant nature
(gastrointestinal disturbance, nausea, vomiting after oral administration, tissue damage at
injection site) and toxic effects on liver and kidney cells (Prescott, 2000). Stevenson
(1980) reported acute tubular necrosis in two dogs after being given an intravenousoverdose of oxytetracycline (130 mg/kg body weight). Severe tubular damage (a Fanconi-
like syndrome) may occur as a result of the toxic degradation products, anhydrotetracycline
and epianhydrotetracycline (Prescott, 2000; Stevenson, 1980; Moalli et al., 1996;
Alexander et al., 1984). Nephrotoxicosis was also reported in feedlot calves (Alexander et
al., 1984) and neonatal foal (Vivrette et al., 1993). Severe damage of structure and
function of the small intestine and excessive accumulation of fat in the liver have been
reported in rats treated for 3 days or longer with high doses of oxytetracycline (400 mg/kg
body weight) (De Jonge, 1973).
In addition, increased sensitivity of the skin to sunlight and superinfection may
occur with tetracyclines, particularly with tetracyclines that are poorly absorbed when
given orally. The use of tetracycline is not recommended during pregnancy or breast
feeding since it may cause permanent discoloration of the teeth and may slow the growth
of the infant's teeth and bones as tetracyclines pass into breast milk.
Oxytetracycline was isolated from actinomycete, Streptoinyces rimosus and is
present in drug products as either the amphoteric base compound, the hydrochloride salt, or
as a quatemary ammonium salt complex. The activity of oxytetracycline against common
pathogenic bacteria is presented in Table 2.3 (Lambert and OGrady, 1992).
In human plasma, 20-35% of oxytetracycline is protein bound (Lambert etal.,
1992) and it distributes widely throughout the body into tissues and body fluids including
sputum, urine, peritoneal and pleural fluids. The primary route of elimination for
oxytetracycline is the kidney via glomerular filtration as parent drug (Hardman and
Limbird, 1999; Lambert and O'Grady, 1992).Table 2.1 Bacterial diseases in alpacas.
Disease Bacteria Clinical signs
Alpaca fever Streptococcus zooepidiinicus Anorexia, recumbency, and fever as high as 41.2°C
(102.6°F)
Anthrax Bacillus anthraces Anorexia, stomachstasis, colic, hematuria, and
hemorrhagic diarrhea
Brucellosis Bruce/la inelitensis Abortion
Blackleg Clostridium chauvei High fever, serohemorrhagic swellings, gas formation in
the heavy muscles of the body and limbs
Botryomycosis Staphylococcus aureus Dermal abscesses
Leptospirosis Leptospira spp. Hemolytic anemia
Colibacillosis Escherichia co/i Diarrhea, weight loss, abdominal distention, no fever,
pica, and debility
John's disease Mycobacteriuin paratuberculosis Weight loss, poor growth, hypoproteinemia, and
terminally diarrhea
Meningoencephalitis Escherichia co/i Weakness, lethargy, neurological signs consisting of
inability to stand, opisthotonus, and depression
Enterotoxemia Type A Clostridiuin perfringens Recumbency with the head stretched forward, eyes closed,
ears directed backwardHO
11
CH3OH
)H00
OHj
V'OH
N(CH3)2
Figure 2.1 Chemical structure of tetracycline.
Table 2.2 Structural formulas of the tetracyclines.
Congener Substituent(s) Position(s)
Chiortetracycline Cl (7)
Oxytetracycline OH,H (5)
Demeclocycline OH,H;Cl (6; 7)
Methacycline 01-I,H;= C112 (5; 6)
Doxycycline OH,H; CH3,H (5; 6)
Minocycline I-I, I-I;N(CH3)2 (6; 7)Table 2.3 Susceptibility of common pathogenic bacteria to oxytetracycline (MIC: tg/mL).
Bacteria MIC (jig/mL)
Staphylococcus aureus 2-8
Streptococcus pyogenes 0.25-1
Streptococcus pneumoniae 0.1-0.25
Neisseria gonorrheae 1-2
Haemophilus influenzae 4-16
Escherichia coli 2-16
Kiebsiella pneuinoniae 16-128
Enterobacter 8-Resistant
Pseudomonas aeruginosa 64-128
Bacillus fragilis 0.5-64
Pharmacokinetic studies of oxytetracycline have been conducted in many animal
species such as goats, sheep, camels, llamas, dogs, rats, hens, cattle, etc. The
pharmacokinetic parameters reported in those animals are listed in Table 2.4.
Interspecies allometric analysis of 44 drugs across various animal species by
Riviere et al. (1997) showed the relationship between elimination half-life of
oxytetracycline and body weight by the allometric equation HL =2.572W°227with the
correlation coefficient (R2) of 0.74 where HL is the half-life in hours and W is the body
weight in kilograms (kg). In addition, Baggot (2001) reported the allometric relationship
between clearance of oxytetracycline and body weight of various mammalian species as
CL =7.96W°73withR2equals to 0.978 where CL is the clearance in mL/min. The values
of half-life and clearance of oxytetracycline predicted from these equations are 6.66 hours
and 2.56 mL/kg/min, respectively, as determined by the mean body weight of alpacas of 66
kg.Table 2.4 Pharmacokinetic parameters of oxytetracycline in some animal species.
Animals
Dose (mg/kg)
Route
Parameters
Goats'
10
IV
Goats'
20
TM (LA)
Sheep2
20
IV
Sheep2
20
TM (LA)
Sheep3
20
TM (LA)
Ka(h) 0.51±0.05 2.41±2.35
Xz (h') 0.11±0.00 0.02±0.00 0.21±0.01 0.05±0.004 0.03±0.02
tJ/2 Ka(h) 1.42±0.17 0.67±0.48
t112,(h) 6.46±0.24 28.0±2.81 3.29* 14.1* 28.0±9.10
MRT (h) 7.90±0.30 37.5±3.49 4.99±0.27 23.0±1.86 35.9±9.71
CLT(L/kg/h) 0.16±0.00 0.19±0.01 1.30±0.01 0.18±0.03**
trnax (h) 3.20±0.23 3.03±0.48 1.79±0.61
Vss (L/kg) 1.23±0.03 0.78±0.02
Vz (L/kg) 1.44±0.04 7.01±1.72
Vc (L/kg) 0.45±0.01 0.20±0.OT
F(%) 79.4 93±4
*= harmonic mean; ** = CL/F (L/kg/h)
1(Escuderoet al.,1994); 2=(Morenoet al.,1998); 3=( Escuderoet al.,1996)Table 2.4 (Continued)
Animals
Dose (mg/kg)
Route
Parameters
Llamas4
10
IV
Llamas4
10
IM (LA)
Camels5
3
IM
One-humpedcamels6
5
IV
One-humpedcamels6
10
IM (LA)
Ka(h1) 7.14±6.3 4.21±0.50
Xz(h1) 0.04±0.02 0.02±0.01 0.10±0.01 0.09±0.02 0.02±0.01
t/ Ka(h) 0.22±0.120 0.17±0.02
t112,5(h) 16.2±6.24* 30.2±9.15* 7.00±0.35 7.7±1.9* 31.3±9.2*
MRT (h) 20.6±6.30 47.8±11.22 7.7±2.8 26.6±2.3
CLT(L/kg/h) 0.04±0.01 0.04±0.02 0.08±0.02
tmax(h) 7.50±3.67 1.10±0.05
Vss(L/kg) 0.82±0.09 0.71±0.17
Vz(L/kg) 0.18±0.73 0.82±0.19
Vc(L/kg) 0.11 ±0.04 0.06±0.04
F (%) 97.8 93.7±32.0
* = harmonicmean
4(A1-Ghazawi, 1998); 5= (El-Gendietal.,1983); 6=(Oukessouetal., 1992)Table 2.4 (Continued)
Animals
Dose (mg/kg)
Route
Parameters
Dairycows7
5
IV
Dairycows7
5
IM
Vealcalves8
40
IV (LA)
Vealcalves8
20
IM (LA)
Calves9
40
IM (LA)
Ka (h') 0.028 0.41±0.14 0.75±0.46
2z (h') 0.08±0.02 0.077 0.029±0.004
tl/2Ka(h) 25 1.86±0.52 2.2±1.8
t117(h) 9.46±1.40 9 93.3±20.9 98.5±24.3 23.9±3.2
MRT (h)
CLT(L/kg/h) 0.09±0.01 0.14±0.15 0.13 ±0.01
tmax(h) 6.26±0.96
Vss (L/kg)
Vz (L/kg) 0.92±0.13 18.14±4.52 18.5±4.52
Vc (L/kg) 0.12±0.02
F (%) 103.2±9.4
7=(Nouwset al.,1985); 8(Meijeret al.,1993); 9=(TerHune and Upson, 1989)
NJTable 2.4 (Continued)
Animals
Dose (mg/kg)
Route
Parameters
Calves'0
20
IV (LA)
Calves'0
20
TM (LA)
African elephant calves"
18.2
IV (LA)
African elephant calves"
18.2
TM (LA)
Ka (h')
Xz (h') 0.039±0.003 0.023±0.002
tI!2 Ka(h) 16.7± 1.04
tI/2X(h) 7.8±0.4 24.4±1.1 18.31±1.3 30.9±2.7
MRT(h) 11.2±0.6 35.3±1.5
CLT(L/kg/h) 0.076±0.003 0.076±0.003 6.17±1.01 6.11 ±0.74
tmax(h) 8.0±0.4
-_______________________________________
Vss (L/kg) 0.86±0.07 2.7±0.2
Vz (L/kg) 2.69±0.48 4.57±0.88
Vc(L/kg) 2.41±0.54 3.56±2.22
F(%) 89.1±4.2
10(Kumar and Malik,1998); 1 1=(Bush etal., 2000)Table 2.4 (Continued)
Animals
Dose (mg/kg)
Route
Parameters
Cattle'2
10
IV
Cattle'2
20
IM (LA)
Buffalo'3
22
IV
Buffalo'3
22
TM
Horses'4
6.6
TV
Ka (h') 0.864
Xz(h') 0.13 ±0.03 0.032±0.003 0.09O.14*** 0.11 ±0.02
Ka(h) 0.8 O.0030.004*** O.042M.066***
5.88* 21.83* 2.82_3.61*** 1O.5_16.5*** 6.08*
MRT(h) 7.27± 1.97
CLT(L/kg/h) 0.0610.087*** 0.13±0.02
tmax (h)
Vss (L/kg) 0.95±0.25
Vz(L/kg) 0.94±0.18 0.94±0.18 0.280.45*** 1.182.15***
Vc (L/kg)
F(%) 51.076.5***
* = harmonicmean; = reported in range
12=(Toutain and Raynaud, 1983); 13=(Varma and Paul, 1983); 14=(Dowling and Russell, 2000)Table 2.4 (Continued)
Animals
Dose (mg/kg)
Route
Parameters
Horses14
6.6
TM
Rabbits13
10
IV
Rabbits'
10
TM
Pigs'6
10
IV
Pigs'7
20
TM (LA)
Ka (h") 0.03±0.012 0.32±0.15
2.z (h) 0.53±0.16
ti/2,Ka(h) 23.15±6.36 2.09±0.92 0.118±0.004
t112(h) 22.08* 1.32±0.40 5.86±0.21
MRT (h) 35.87±9.816 1.62±0.66 5.15±2.10 31.3±4.3
CLT(L/kg/h) 0.43±0.14 0.58±0.16** 0.22±0.02
tmax (h) 1.87±1.58 1.5 4.0±2.7
Vss (L/kg) 0.67±0.27
Vz(L/kg) 0.86±0.29 1.84±0.18
Vc (L/kg) 0.19±0.12
F(%) 83.1±15.0
*= harmonic mean;**CL/F (L/kg/h)
14=(Dowling and Russell, 2000); 15=(McElroyet al.,1987); 16=(Pijperset al.,1990); 17=(Archimbaultet al.,1994)Table 2.4 (Continued)
Animals
Dose (mg/kg)
Route
Parameters
18
Piglets
20
IV
19
Dogs
5
IV
NI Hens
10
IV
21 Rats
20
IV (LA)
Rats
20
IM (LA)
Ka (h')
Xz(h1) 0.03±0.003 0.04±0.02
tI!2 Ka(h) 0.12±0.03
t112.(h) 14.1±2.85 6.02± 1.51-
27.26± 3.54 22.0± 10.1
MRT(h) 6.84±0.63
CLT(L/kg/h) 0.25±0.03 0.25±0.08 0.10±0.08 0.131±0.041 0.58±0.04
tmax (h)
Vss (L/kg) 0.71±0.06
Vz (L/kg) 5.18±1.67 2.10±0.42 068±0.05 0.79±0.22 5.09±1.66
Vc (L/kg) 0.29±0.05 0.24±0.05 0.15±0.01
F (%)
**= CL/F (L/kg/h)
18(Mevius etal., 1986); 19=(Baggotetal., 1977); 20=(Moreno etal., 1996); 21(Curl etal., 1988)Table 2.4 (Continued)
Animals
Dose (mg/kg)
Route
Parameters
Foals22
60
IV (LA)
Rainbowtrout23
60
IV
Rainbowtrout23
60
TM
Human24
500 mg
Oral
Ka (h') 0.718±0.080
Xz(h) 0.008±0.001 0.135±0.017
tl/7Ka(h) 1
tl/2XZ(h) 7.30* 89.5±8.7 94.7±16.0 5.22±0.65
MRT(h)
CL1(L/kg/h)
10.6±3.58
0.19 ±0.06 0.016±0.OÔ1
tmax(h)
-
4 2.9± 0.28
Vss(L/kg) 2.17±0.24
--_________________________________
Vz(L/kg) 2.19±0.47 2.10±0.30
Vc (L/kg) 0.94±0.19 0.09±0.04
j 0.23±0.02
F(%) 85
* = harmonicmean
22=(Papichet al.,1995); 23= (Grondeletal., 1989); 24=(Wojcickiet at,1985)Abbreviations used in Table 2.4:
Ka = absorption rate constant, t1/7Ka= absorption half-life, Xz = elimination rate constant,
t112,= elimination half-life, MRT = mean residence time,CLT =total body clearance, tflax
= time when maximum concentration was obtained, Vss = apparent volume of drug
distribution at steady state, Vz = terminal volume of distribution, Vc = apparent volume of
the central compartment, and F = bioavailability.
Information on the pharmacokinetics of oxytetracycline in alpacas is speculative as
drug disposition in alpacas is considered to be equivalent to llamas so the appropriate
dosage regimen of oxytetracycline in alpacas has not been defined yet. The purpose of this
study was to investigate the disposition and pharmacokinetics of oxytetracycline in alpacas
following intravenous and intramuscular administration. Based on the pharmacokinetic
parameters obtained in the study, a proper dosing regimen will be developed in order to
improve dosing of oxytetracycline and drug treatment of alpacas.
MATERIALS AND METHODS
Drugs and chemicals:
Oxytetracycline hydrochloride (Biomycin C®, Boehringer Ingelheim Animal
Health, Inc., St. Joseph, Missouri, USA, 100 mg/mL) was used for intravenous (IV)
administration, while long-acting intramuscular (LA-IM) administration of
oxytetracycline was by Liquamycin®LA-200 (Pfizer Animal Health, Exton, Pennsylvania,
USA, 200 mg/mL). Oxytetracycline hydrochloride, trichloroacetic acid, disodium EDTA,
citric acid monohydrate, and N, N-dimethyl formamide (HPLC grade) were obtained from
SIGMA Chemical Co. (St. Louis, Missouri, USA). Sodium citrate anhydrous was obtained
from SPECTRUM (New Brunswick, New Jersy, USA). Potassium nitrate was obtained
from Mallinckrodt (Paris, Kentucky, USA). Methanol (HPLC grade) was obtained from
Fisher Scientific (Fair Town, New Jersy, USA).19
Animals:
Six healthy adult alpacas, three females and three gelded males in the Veterinary
Medicine Animal Isolation Laboratory at Oregon State University, weighing between 5 9.6-
71.9 kg, age 4-8 years, were used in the study. All animals received a routine checkup
including vaccination and deworming prior to the study. Routine health treatments were
completed at least two weeks and no longer than a month before the start of the study.
Grass hay and water were availablead libitum.
Administration of drugs and sampling protocol:
Initially a single dose of 10 mg/kg body weight of Biomycin C was administered
intravenously through the jugular vein. A week later, the same animals were given the
same dose ofLiquamycin®LA200 into the semimembranosus hind leg muscle.
Blood samples were collected from the jugular vein before drug administration and
at 10, 20, and 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after IV administration.
The same blood sampling time scheme was performed after TM administration except
additional samples were taken at 48 and 72 hours. Before taking the next sample, 8 mL of
blood was drawn through the catheter and discarded to remove the heparin saline flush of
the previous blood sample, ensuring a proper blood sample was drawn. After each blood
sample was collected, the catheter was flushed with heparinized normal saline. All blood
samples were transferred to evacuated tubes coated with 15.0 mg EDTA powder and mixed
gently. Plasma was separated by centrifugation at 1,500 x g for 15 minutes and stored at
-20°C until assayed.
Analytical method:
The plasma concentrations of oxytetracycline were measured by High Performance
Liquid Chromatography (HPLC) with a system P2000 pump, a SP 8880 autosampler, a
Spectra 100 variable wavelength detector and a ChromJet integrator (Spectra-Physics, San
Jose, California, USA) using the method of Escuderoet al.(1994). A sample of plasma
(400 iL) was deproteinated with 100 j.tL of 15% trichloroacetic acid in methanol. The
mixture was vortexed for 1 minute, placed on ice for 15 minutes, and centrifuged at 10,000
x g for 10 minutes. Samples (100 tL) of the supernatant were injected ontoC18column20
(Phenomenex, Torrance, California, USA) and scanned by the ultraviolet detector whose
wavelength was set at 357 nm. The mobile phase was composed of 30% N, N-dimethyl
formamide and 70% water, containing 0.0 13 M Sodium citrate, 0.01 M potassium nitrate,
0.00 1 M disodium EDTA, and 0.05 M citric acid monohydrate with the pH adjusted to 3.5.
Calibration curves for the quantification of oxytetracycline in alpaca plasma
samples were obtained by plotting the peak areas against the concentrations of
oxytetracycline prepared as standard solutions. The calibration curves were determined by
linear regression analysis to be linear. Correlation coefficients of calibration curves were
greater than 0.999. The concentrations of oxytetracycline in alpaca plasma samples were
calculated from the calibration curve using inverse prediction.
The overall percent coefficient of variation (% CV) of the oxytetracycline assay
was 3.26%. The % CV of oxytetracycline concentration in prepared standard solutions is
shown in Table 2.5. The limit of quantification was 0.24 jig/mL.
Table 2.5 The percent coefficient of variation (% CV) of oxytetracycline concentration in
prepared standard solutions.
Actual conc.
(j.ig/mL)
Average of predicted
conc. (jig/mL)
SD %theoretical
conc.
%CV
0.4 0.425 0.156 106.3 36.71
0.8 0.748 0.168 93.50 22.46
2.0 1.972 0.168 98.60 8.519
4.0 4.003 0.279 100.1 6.970
8.0 7.966 0.255 99.58 3.201
16.0 15.99 0.431 99.94 2.695
20.0 20.21 0.537 100.1 2.657
40.0 39.81 0.738 99.53 1.854
60.0 59.74 0.957 99.57 1.602
Grand mean of% theoretical conc. = 99.8
Grand SD of mean % theoretical conc. = 3.25
Overall %CV = 3.2621
Pharmacokinetic analysis:
The plasma concentration-time curves of oxytetracycline following TV and TM
administration were fitted for each individual alpaca by both compartmental and
noncompartmental approaches with WinNonlin Professional Version 3.2 software
(Pharsight Corporation, Mountain View, California, USA) using a weighting factor of
1/plasma concentration. The optimum number of first-order rate processes in the
predictive equation was selected on the basis of the minimal Akaike's information criterion
(Wagner, 1993; Yamaoka et al., 1978). Oxytetracycline plasma concentration-time
profiles after IV administration were best described by a linear three-compartment open
model while that of TM administration were fitted using two-compartment open model with
two parallel first-order input functions.
For compartmental analysis, the pharmacokinetic parameters were calculated from
the equation best describing the plasma concentration-time profiles. The area under the
curve (AUC0) was calculated from the coefficients and exponential constants of the
equation explaining the data.
I,
Cp =Cje*t) (1)
AUC0= (2)
where Cp is the plasma concentration, ?is the exponential constant, C, is the coefficient,
and n is the number of exponential terms in the equation.
The total body clearance (CLT) was calculated according to the following equation.
CL
Dose
AUC0
MRT is the mean residence time and is equal to
(3)
MRTAUMC0
(4)
A UC0
AUMC0is the area under first moment versus time curve, and was calculated from
AUMC0= (5)22
The apparent volume of distribution at steady state (Vss) was calculated according to
VSS=CLTXMRT (6)
Half-lives were calculated according to
0.693
(7)
The bioavailability (F) of oxytetracycline after TM injection was estimated according to the
equation
F
AUCIM /Dose/M
(8)
AUCIV /Dose1
For noncompartmental analysis, tfllax and Cnax were determined from the observed
data. The MRT and terminal half-lives were calculated as stated above. The area under
the curve (AUC0) and the area under the first moment curve (AUMC0) were calculated
by the trapezoidal rule up to the last sampling time point(AUC0 AUMCU) and
extrapolated to infinity
(AUCtO,AUMC) using the equations
Ct AUC =- (9)
2z
AUMC
t*CtCf
2z
(10)
Therefore, AUCØ= AUCO + (11)
t*CtCt
and AUMC0AUMC01+ +-- (12)
Az2z
The terminal volume of distribution (Vz) was calculated by the following equation.
(13)
2z
RESULTS
The plasma concentration-time curves for each alpaca were individually fitted
following both IV and LA-TM administration. Tables 2.6 and 2.7 show the plasma23
concentrations of oxytetracycline in each alpaca after IV and LA-TM administration given
at a single dosage of 10 mg/kg body weight. Also listed in Tables 2.6 and 2.7 are the
average oxytetracycline concentrations with their standard deviations at each time point.
The semilogarithmic plot of individual plasma concentrations of oxytetracycline after IV
and LA-TM administration are presented in Figures 2.2 and 2.3, respectively, while the
mean plasma concentration of oxytetracycline for six alpacas following IV and LA-TM
administrations along with the standard deviations are depicted in Figures 2.4 and 2.5,
respectively.
The plasma concentration-time profile after IV administration showed declining
oxytetracycline plasma concentrations that followed a ti-exponential manner, as
demonstrated in Figure 2.6, according to the equation
CpCie_A*t+C2e_/2*f+C3e3*t (14)
where Cp is the plasma concentration of oxytetracycline at time t, C,C7,andC3are the
coefficients, and X,X7,andX3are the exponential constants for the triexponential equation
describing the oxytetracycline plasma concentration-time curve.
For LA-TM administration, none of the one- and two-compartment open models
with first-order or zero-order input produced a good fit to the absorption phase of the
plasma concentration-time profiles, indicating that the absorption process is atypical. Loo-
Riegelman and deconvolution techniques were applied to the data to better understand the
absorption process. The results are presented in Figures 2.7, 2.8, 2.9, and 2.10,
respectively. Based on these two approaches, the absorption of oxytetracycline from the
intramuscular injection site occurred in two parallel phases. Initially, a rapid absorption
phase having a mean absorption rate constant (Ka1) of 0.36 ± 0.17 mm' (21.5 ± 10.0 h')
predominates followed by the appearance of a slower absorption phase having a mean
absorption rate constant (Ka2) of 0.0003 ± 0.0001min1(0.016 ± 0.003 h').
Oxytetracycline plasma concentrationtime curves were fitted to a two-compartment open
model with two parallel first-order inputs, as demonstrated in Figure 2.11, according to the
equation
Cp =Ae_i*t _Bel*t+Ce_2*t _De_l*t (15)where Cp is the plasma concentration at time t. A, B, C, and D are the coefficients for a
tetra-exponential equation. X andX2are rapid and slow disposition rate constants,
respectively.Ka1is the first-order absorption rate constant for the rapid absorption phase
andKa2is the first-order absorption rate constant for the slow absorption phase.
Pharmacokinetic parameters of oxytetracycline after IV and LA-TM
administrations obtained from compartmental and noncompartmental analysis are
summarized in Tables 2.8, 2.9, 2.10, and 2.11, respectively.Table 2.6 Plasma concentrations of oxytetracycline (jig/mL) in six alpacas at each sampling time point after 10 mg/kg IV
administration.
Time Plasma oxytetracycline concentrations (jig/mL)
(mm) Alpaca 1 Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
10 32.5704 27.2641 28.9542 38.2415 40.5733 30.5350 33.0231 5.2982
20 18.3692 17.3973 18.1057 21.9797 19.0170 17.9367 18.8009 1.6455
30 13.3840 13.3082 12.5237 15.8013 13.1418 12.1520 13.3852 1.2779
60 8.2271 8.3398 8.1486 9.7249 96022 7.9958 8.6731 0.7763
90 6.9461 6.4965 7.1930 7.6647 7.3286 6.7014 7.0550 0.4277
120 5.2924 5.6748 5.5396 6.8233 6.3227 5.5692 5.8703 0.5805
180 4.2508 4.1711 4.1851 4.5919 4.7794 3.8494 4.3046 0.3317
240 3.3763 3.3290 3.7678 4.2149 4.4134 3.5208 3.7704 0.4525
360 2.8006 2.6208 2.7540 3.2209 3.4627 2.9915 2.9751 0.3173
480 2.2692 2.0030 2.5581 2.6625 2.6055 2.1445 2.3738 0.2728
720 1.5275 1.6185 1.3260 1.9718 1.9662 1.5509 1.6602 0.2583
1440 0.8940 0.5588 0.4860 0.8285 0.8673 0.6869 0.7203 0.1706Table 2.7 Plasma concentrations of oxytetracycline (j.tg/mL) in six alpacas at each sampling time point after 10 mg/kg
LA-TM administration.
Time Plasma oxytetracycline concentrations (ig/mL)
(mm) Alpaca I Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
10 1.5678 1.5231 0.5864 1.7079 0.7254 0.7471 1.1429 0.5069
20 1.6594 1.6260 0.6005 1.7185 1.0877 1.0562 1.2914 0.4481
30 1.8971 1.6277 0.6621 1.8370 1.2262 1.1109 1.3935 0.4792
60 1.9465 1.8346 0.7711 1.9966 1.6699 1.3274 1.5910 0.4687
90 1.9467 1.8457 1.1430 2.0699 1.6805 1.5169 1.7004 0.3356
120 1.9635 1.8980 1.3474 2.3096 1.7034 1.7130 1.8225 0.3209
180 1.9663 1.9031 1.3911 2.3026 1.7422 1.5271 1.8054 0.3273
240 1.9868 1.9311 1.4431 2.2289 1.8806 1.4980 1.8281 0.3022
360 1.5579 1.9425 1.5057 2.1218 1.9502 1.3576 1.7393 0.3050
480 1.4060 1.7141 1.4000 2.0601 2.0722 1.2293 1.6470 0.3604
720 1.2877 1.6026 1.2218 1.9486 1.3118 1.1540 1.4211 0.3006
1440 1.2186 1.1900 0.8423 1.5867 1.1996 0.8503 1.1479 0.2771
2880 0.9325 0.6514 0.8084 0.8762 0.7151 0.6962 0.7800 0.1106
4320 0.6200 0.4298 0.5 123 0.4874 0.5046 0.4845 0.5064 0.062727
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Figure 2.2 Semilogarithmic plot of individual oxytetracychne plasma concentration-time
curve after a 10 mg/kg single dose TV administration.
10
-J
E
C)
C.)
E
I-
C.)
0
0
0.1
0 500 1000 1500 2000 2500 3000 3500 4000 4500 5000
Time (mm)
Figure 2.3 Semilogarithmic plot of individual oxytetracycline plasma concentration-time
curve after a 10 mg/kg single dose LA-TM administration100
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Figure 2.4 Semilogarithmic plot of mean oxytetracycline plasma concentration-time curve
along with standard deviations after a single dose of 10 mg/kg was administered
intravenously.
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Figure 2.5 Semilogarithmic plot of mean oxytetracycline plasma concentration-time curve
along with standard deviations after a single dose of 10 mg/kg was administered
intramuscularly.29
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Figure 2.6 Semilogarithmic plot of average plasma concentration-time curve of
oxytetracycline in alpacas after IV administration at a single dose of 10 mg/kg.120
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Figure 2.7 Plot of percent remaining to be absorbed versus time (mm) after 10 mg/kg LA-
TM administration using Loo-Riegelman approach.
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Figure 2.8 Semilogarithmic plot of percent remaining to be absorbed versus time (mm)
after 10 mg/kg LA-TM administration using Loo-Riegelman approach.120
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Figure 2.9 Plot of percent remaining to be absorbed versus time(mm)after 10 mg/kg LA-
IM adminisfration using deconvolution approach.
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Figure 2.10 Semilogarithmic plot of percent remaining to be absorbed versus time (mm)
after 10 mg/kg LA-IM administration using deconvolution approach.32
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Figure 2.11 Semilogarithmic plot of average plasma concentration-time curve of
oxytetracycline in alpacas after LA-TM administration at a single dose of 10 mg/kg.Table 2.8 Pharmacokinetic parameters of oxytetracycline after 10 mg/kg IV administration using compartmental analysis.
Parameters Alpaca I Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
C1(ig/mL) 55.5 34.8 43.3 38.7 117 51.9 57.0 30.8
C2(ig/mL) 9.97 9.35 8.24 9.94 10.8 8.58 9.48 0.96
C3(jig/mL) 3.62 3.97 5.08 4.70 5.20 4.13 4.45 0.64
X1(min1) 0.102 0.084 0.094 0.072 0.151 0.101 0.101 0.027
X2(min') 0.0120 0.0123 0.0140 0.0119 0.0146 0.0124 0.0128 0.0012
X3(min1) 0.00102 0.00134 0.00167 000121 0.00129 0.00128 0.00130 0.00021
tl/2,xI(min) 6.81 8.24 7.38 9.68 4.60 6.89 6.90* 1.69
t112,x2(min) 57.9 56.6 49.5 58.5 47.5 55.7 53.9' 4.62
tl/2,?3(min) 679 518 414 575 537 542 533* 85.8
AUC
(jgmin/mL)
4923 4148 4082 5419 5557 4434 4761 638
CLT
(mL/kg/min)
2.03 2.41 2.45 1.85 1.80 2.26 2.13 0.28
MRT(min) 721 552 455 628 573 583 585 87.5
Vc(mL/kg) 145 208 1767 188 74.7 155 158 46.6
Vss(mL/kg) 1464 1331 1116 1189
-
1031 1314 1241 159
* = harmonicmeanTable 2.9 Pharmacokinetic parameters of oxytetracycline after 10 mg/kg IV administrationusing noncompartmental analysis.
Parameters Alpaca 1 Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
Xz(min') 0.0011 0.0014 0.0016 0.0013 0.0013 0.0013 0.00133 0.00016
tI!2)(fl1ff1) 608 486 421 535
-
515 540 515* 63.0
MRT(min) 727 514 448
-
590 617 605 583 95.2
AUC
(igmin/mL)
4964 4221 4144 5529 5667 4552 4846 652
CLz
(mL/kg/min)
2.01 2.37 2.41 1.81 1.76 2.20 2.09 0.28
Vz(mL/kg) 1831 1692 1508 1391 1357 1690 1578 189
* = harmonicmeanTable 2.10 Pharmacokinetic parameters of oxytetracycline after 10 mg/kg LA-IM administration using compartmental analysis.
Parameters Alpaca 1 Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
A (tg/mL) 0.57 0.53 0.46 0.88 0.85 0.10 0.56 0.29
B (j.ig/mL) 0.79 0.79 1.50 1.14 1.35 1.05 1.10 0.29
C (ig/mL) 1.43 1.76 1.34 1.80 1.50 1.50 1.55 0.18
D (j.ig/mL) 1.21 1.50 0.30 1.54 1.00 0.55 1.02 0.51
Ka1(min') 0.49 0.37 0.48 0.50 0.10 0.21 0.36 0.17
Ka7(min') 0.0002 0.0003 0.0002 0.0003 0.0003 0.0003 0.0003 0.0001
tl/7Kal (mm) 1.41 1.87 1.44 1.39 6.92 3.25 1.93* 2.18
tI/2,Ka2(min) 3465 2068 2888 2576
-
2665 2415 2613* 472
21(min') 0.059 0.010 0.012 0.016 0.010 0.031 0.025 0.019
X2 (min') 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.0002
t1(mm) 11.7 69.3 57.7 58.2 69.2 22.5 31.1* 24.8
tl/2,?2(min) 630 532 410 578 545 538 530* 72.7
AUC
(jg'min/mL)
7645 5574 5725 7560 6304 5264 6345 1031
CL/F
(mL/kg/min)
1.308 1.794 1.747 1.323 1.586 1.899 1.614 0.278
* = harmonicmeanTable 2.11 Pharmacokinetic parameters of oxytetracycline after 10 mg/kg LA-IM administration using noncompartmental analysis.
Parameters Alpaca I Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
tmax(min) 240 360 360 120 480 120 280 145
(tg/mL) 1.99 1.94 1.51 2.31 2.07 1.71 1.92 0.28
2.z(mm1) 0.0002 0.0004 0.0003 0.0004 0.0003 0.0002 0.0003 0.0001
tl/7xZ(min) 2890 1936 2188 1752 2376 3460 2308* 638
CLz
(mL/kg/min)
1.89 2.13 2.42 1.70 2.08 2.49 2.12 0.30
MRT(min) 3685 2815 4287 2535 3327 4802 3575 865
AUC
(ig.min/mL)
5299 4698 4138 5898 4807 4010 4808 711
Vz(mL/kg) 1715 1520 1510 1304 1600 1918 1595 208
F(%) 107 111 99.9 107
j
84.8 88.1 99.6 10.9
* = harmonicmean37
DISCUSSIONS AND CONCLUSION
The pharmacokinetic behavior of oxytetracycline in alpacas after IV administration
of a single dose of 10 mg/kg was best described by a three-compartment open model on the
basis of minimal AIC. This conclusion is in agreement with the results of previous studies
carried out on various animal species such as one-humped camels (Oukessou ci al., 1992),
rats (Curl ci' al., 1988), dairy cows (Nouws etal., 1985), dogs (Baggot et al., 1977), piglets
(Mevius etal., 1986), and rainbow trout (Black ci al., 1991). A two-compartment open
model gave the best fit in goats (Escudero el al., 1994), dairy goats (Rule ci al., 2001),
hens (Moreno ci' al., 1996), and pigs (Pijpers et al., 1990). The rapid distribution phase of
oxytetracycline after IV administration to alpacas had a mean half-life of 6.90 ± 1.69 mm
(0.12 ± 0.03 h). A slower distribution phase had a half-life of 53.9 ± 4.62 mm (0.91 ± 0.08
h). The elimination half-life of 533 ± 85.8 mm (8.88 ± 1.43 h) was similar to that reported
for dairy cows (9.46 ± 1.40 h) by Nouws ci al. (1985), but it is a longer half-life compared
to 7.70 ± 1.90 h published for one-humped camels (Oukessou ci al., 1992). For alpacas,
the apparent volume of distribution of the central compartment (Vc ) was 0.16 ± 0.05 L/kg
whereas 0.12 ± 0.01 L/kg and 0.24 ± 0.05 L/kg were reported in dairy cows (Nouws etal.,
1985) and dogs (Baggot etal., 1977), respectively. The apparent volume of distribution at
steady state (Vss) for the alpaca was 1.24 ± 0.16 L/kg, while 0.71 ± 0.17 L/kg was found in
one-humped camels (Oukessou etal., 1992).
The total body clearance of 0.13 ± 0.02 L/kg/h (2.13 ± 0.28 mL/kg/min) in alpacas
was about the same as compared with 0.13 ± 0.04 L/kg/h in rats (Curl etal., 1988), 0.10 ±
0.08 L/kg/h in hens (Moreno etal., 1996), and 0.13 ± 0.02 L/kg/h in horses (Dowling and
Russell, 2000), whereas 0.08 ± 0.02 L/kg/h was reported in one-humped camels (Oukessou
etal., 1992).
With long-acting TM administration, a two-compartment open model with two
parallel first-order inputs best described the plasma concentration-time profiles of
oxytetracychne in alpacas. The value of the smallest disposition rate constant (Xz) usually
designated as the elimination rate constant was significantly different from the elimination
rate constant obtained from IV alpaca oxytetracycline data (p-value < 0.05). The value ofthe absorption rate constant of the slower absorption phase (Ka2) was similar to the value
of the elimination rate constant obtained from the terminal slope of the oxytetracycline
plasma concentration-time curve after TM administration in alpacas, indicating that the
long-acting formulation followed a flip-flop model. Thus the apparent elimination phase
of the long-acting TM formulation appears to be dependent on the very long absorption
process of oxytetracycline from the injection site. This phenomenon was also reported in
goats (Escuderoetal., 1994), veal calves (Schifferlietal.,1982), cattle (Toutain and
Raynaud, 1983), sheep (Morenoetal., 1998), and horses (Dowling and Russell, 2000).
Bioavailability of oxytetracycline in alpacas after LA-IM administration was 99.6
± 10.9 %, compared to 93.0 ± 4.0%, 93.7 ± 32%, 103 ± 9.4 %, and 83 ± 15 % reported in
sheep (Morenoetal., 1998), one-humped camels (Oukessou etal., 1992), veal calves
(Meijer et al., 1993), and horses (Dowling et al., 2000), respectively.
In alpacas, most of the susceptible bacteria have MIC2 j.xg/mL. In order to
maintain the oxytetracycline plasma concentrations greater than 2 jtg/mL, 8 mg/kg of TV
injection should be given every 12 hours and a loading dose of 20 mg/kg and an
maintenance dose of 10 mg/kg of LA-TM formulation should be administered every 48
hours. A steady state trough concentration of 2.26 and 3.04 tg/mL will be achieved after
IV and LA-IM administrations, respectively, as determined by superposition method.
Table 2.12 Recommended dosage regimens of oxytetracycline in alpacas.
Formulation Dose Dosing intervalTrough steady stateCost for 5 days
(mg/kg) (h) concentration (S)
(jig/mL)
IV 8 12 2.26 3.30
LA-TM 20 (LD) 48 3.04 2.00
10 (MD)
LD=Loading dose
MD=Maintenance dose39
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COMPARATIVE PHARMACOKINETICS OF OXYTETRACYCLINE IN LLAMAS
AND ALPACAS FOLLOWING INTRAVENOUS AND LONG-ACTING
INTRAMUSCULAR ADMINISTRATION
Triporn Wattananat, Mutasim AI-Ghazawi, J. Mark Christensen,
and Bradford B. Smith45
ABSTRACT
This chapter explores the pharmacokinetics of oxytetracycline in alpacas following
a single dose of 10 mg/kg body weight given by intravenous injection and intramuscular
administration of a long acting formulation and compares the pharmacokinetic parameters
with the results previously obtained in llamas. After IV administration, a three-
compartment open model best described the plasma concentration-time profiles of both
llamas and alpacas. There were significant differences between these two animals in
several of the pharmacokinetic parameters. With long-acting IM administration, a one-
compartment open model best described the plasma concentration-time curves in llamas
whereas a two-compartment open model gave a better fit to the plasma concentration-time
profiles in alpacas. The biphasic absorption was shown in both animals. Since the
disposition of oxytetracycline in llamas and alpacas is different, the dosage regimen of
oxytetracycline should be defined differently in order to get the same therapeutic effect in
llamas and alpacas.INTRODUCTION
New World camelids, also called South American camelids (SACs), are classified
as 4 species, Lama glama (Llama), Lama pacos (Alpaca), Lama guanicoe (Guanaco), and
Vicugna vicugna (Vicuna). Both the llama and the alpaca exist only as domestic species
whereas the guanaco and the vicuna are wild species. The llama is the largestin size of the
four SACs (Fowler, 1998).
Llamas serve as pack, driving, and companion animals. They are used for
breeding stock, Show, producing fiber (wool), and livestock guardians. Well-trained
llamas can be utilized as pet therapy with elderly and disabled people because of their
calming effect (Birutta, 1997 and Fowler, 1998). Alpacas are mainly used for producing
commercial fiber production (Fowler, 1998).
Although llamas and alpacas are different in size and physical characteristics, they
are able to interbreed and produce fertile offspring. It is questionable whether they are one
or two separate species. If they are treated as a different species, it is certain that drug
disposition in the two animals is different. Therefore, dosage regimens should be defined
differently in order to get the same therapeutic effect.
The objective of this study is to compare the pharmacokinetics of oxytetracycline
in the alpaca with results previously obtained in the llama (Al-Ghazawi, 1998) and
determine if llamas and alpacas drug disposition is similar.
RESULTS
The plasma concentration-time profiles of oxytetracycline followinga single dose
of 10 mg/kg IV administration in both llamas and alpacaswere best fitted to a three-
compartment open model. The comparison of mean plasma concentrations versus time
along with standard deviations after an IV dose in both animals is shown in Table 3.1.
With TM administration of a long acting formulation (LA-IM),a one-compartment
open model best described the plasma concentration-time curves in llamas whereas a two-47
compartment open model gave a better fit to the plasma concentration-time profiles in
alpacas. To better understand the absorption process after the TM dose, Loo-Riegelman
and deconvolution methods were used and biphasic absorption phases were found in both
llamas and alpacas. Two parallel first-order absorption phases were demonstrated in both
animals. The comparison of average oxytetracycline plasma concentrations along with
standard deviations after LA-TM dose in llamas and alpacas is depicted in Table3.2.
Mean plasma concentration-time curves of oxytetracycline in llamas and alpacas
following IV and LA-IM administration at a single dose of 10 mg/kg body weight are
shown in Figures3.1and3.2,respectively. Noncompartmental analysis of the plasma
concentration-time curves of oxytetracycline in llamas and alpacas after IV and LA-TM
dosing was also performed. The mean pharmacokinetic parameters for llamas and alpacas
following IV and LA-IM administration obtained from compartmental and
noncompartmental analysis are listed in l'ables3.3, 3,4, 3.5,and3.6,respectively. The
Student's t-test and Mann-Whitney U-test were used to determine significant differences
(p-value <0.05)between pharmacokinetic parameters and the results are also shown in
Tables3.3, 3.4, 3.5,and 3.6.Table 3.1 Comparison of oxytetracycline plasma concentrations (mean ± SD, pg/mL) in
llamas and alpacas after a single dose (10 mg/kg) IV administration.
Time (mm) Llamas Alpacas
10 44.11±5.33 33.02±5.30
20 32.37± 3.50 18.80± 1.65
30 24.33±2.79 13.39±1.28
60 15.84±0.89 8.67±0.78
90 12.72± 1.16 7.06± 0.43
120 11.10± 1.03 5.87±0.58
180 10.11±0.90 4.31±0.33
240 8.55±0.85 3.77±0.45
360 7.08±0.67 2.98±0.32
480 6.54±0.47 2.37±0.27
720 6.35±0.94 1.66±0.26
1440 3.76±1.53 0.72±0.17Table 3.2 Comparison of oxytetracycline plasma concentrations (mean ± SD, jig/nit) in
llamas and alpacas after a single dose (10 mg/kg) LA-TM administration.
Time (mm) Llamas Alpacas
10 1.69± 1.10 1.14± 0.51
20 3.08±0.10 1.29±0.45
30 3.63±0.94 1.39±0.48
60 3.76±0.95 1.59±0.47
90 3.96±0.84 1.70±0.34
120 4.19± 1.03 1.82±0.32
180 4.33±0.95 1.81±0.33
240 4.60±1.11 1.83±0.30
360 4.75±1.28 1.74±0.31
480 4.36± 1.10 1.65 ±0.36
720 4.89± 1.64 1.42±0.30
1440 3.90±1.24 1.15±0.28
2880 2.49±0.79 0.78±0.11
4320 1.25±0.41 0.51±0.061000
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Figure 3.1 Semilogarithmic plot of average plasma concentration-time curves of
oxytetracycline in llamas and alpacas after IV administration at a single dose of 10 mg/kg.
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Figure 3.2 Semilogarithmic plot of average plasma concentration-time curves of
oxytetracycline in llamas and alpacas after LA-TM administration at a single dose of 10
mg/kg.Table 3.3 Pharmacokinetic parameters of oxytetracycline (mean + SD) aftera single dose (10 mg/kg) IV administration using
compartmental analysis.
Parameters Llamas Alpacas Level of
significance
p-value Number of subjects
required to be statistical
significant different
C1(jig/mL) 72.4±30.9 57.0±30.8 NS 0.204 31
C2(tg/mL) 18.1±11.1 9.48 ±0.96 P<0.05 0.025
C3(jig/mL) 9.35±0.69 4.45±0.64 P<0.05 <0.0005
X1(min) 0.08±0.05 0.10±0.03 NS 0.238 31
X2 (mm1) 0.022±0.015 0.013±0.001 NS 0.221 238
X3(min') 0.0007±0.0001 0.0013±0.0002 P<0.05 <0.0005
t,21(mm) 8.27*±4.59 6.90*±1.69 NS 0.221 41
(mm) 455*±29.6 539*±4.62 NS 0.397 32
(mm) 1025*±362 533*±85.8 P<0.05 0.022
MRT (mm) 1425±517 585±87.5 PK0.05 0.010
CLT(mL/kg/min) 0.62±0.16 2.13±0.28 p <0.05 <0.0005
Vc(mL/kg) 113 ±38.8 158±46.6 P<0.05 0.049
Vss (mL/kg) 818±95.5 1241±159 PK0.05 <0.0005
AUC(tg.min/rnL) 17195±2517 4761±638 P<0.05 0.010
* = harmonicmeanTable 3.4 Pharmacokinetic parameters of oxytetracycline (mean ± SD) after a single dose (10mg/kg) IV administration using
noncompartmental analysis.
Parameters Llamas Alpacas Level of significance p-value
Xz (min') 0.0007±0.0003 0.00 13±0.0002 P <0.05 <0.0005
tI/2,XZ(min) 975*±374 515*±63.0 P<0.05 0.019
CLz (mL/kg/min) 0.62±0.22 2.09±0.28 P<0.05 <0.0005
Vz(mL/kg) 842± 120 1578± 189 P<0.05 <0.0005
MRT(min) 1236±378 583±95.2 P<0.05 0.010
AUC(tgmin/mL) 17953 ±7153 4846± 652 P<0.05 0.010
* = harmonicmean
NJTable 3.5 Phannacokinetic parameters of oxytetracycline (mean + SD) aftera single dose (10 mg/kg) LA-IM administration using
compartmental analysis.
Parameters Llamas Alpacas Level of significance p-value
Ka (min') 0.119±0.105 0.359±0.167 P <0.05 0.007
Ka,(min1) 0.0031±0.0029 0.0003±0.0001 P <0.05 0.005
tI/2,Kal (mm) 5.81*±11.8 1.93*±2.18 P <0.05 0.035
tl/2,Ka2(min) 222*±365 2613*±472 P<0.05 <0.0005
Ke(min1) 0.0005 ± 0.0002 0.0013 ± 0.0002 P < 0.05 0.010
tl/2Ke(mifl) 1531*±600 530*±72.7 P<0.05 0.010
AUC (jig.min/mL) 16818±4480 6345±1031 P <0.05 0.010
*= harmonic meanTable 3.6 Pharmacokinetic parameters of oxytetracychne (mean + SD) aftera single dose (10 mg/kg) LA-IM administration using
noncompartmental analysis.
Parameters Llamas Alpacas Level of
significance
p-value Number of subjects
required to be statistical
significant different
Cn1ax(j.ig/mL) 5.11±1.61 1.92±0.28 P<0.05 0.010
tniax(min) 450±220 280± 145 NS 0.076 9
Xz(mm1) 0.0004±0.0001 0.0003±0.0001 NS 0.093 8
t11,(min) 1812*±549 2308*±638 NS 0.092 11
CLz (mL/kg/min) 0.63±0.25 2.12±0.30 P<0.05 <0.0005
Vz(mL/kg) 1748±730 1595 ±208 NS >0.25 73
MRT (mm) 2867±673 3575±865 N5 0.076 10
AUC (g'min/mL) 17348±4937 4808±771 P<0.05 0.0 10
* = harmonicmean
Lf55
DISSCUSSIONS AND CONCLUSION
There were statistically significant differences between llamas and alpacasin
several of the oxytetracycline pharmacokinetic parameters. After IV administration, the
elimination rate constant (0.0007 ± o.000ivs0.0013 ± 0.0002 min1), elimination half-life
(1025 + 362 V5 533 ± 86 mm), area under the curve (17195 ± 2517 V5 4761 + 638
i.g.min/mL), total body clearance (0.62 ± 0.16 V5 2.13 ± 0.28 mL/kg/min), terminal
volume of distribution (842 ± 120 Vs 1578 ± 189 mL/kg), and apparent volume of
distribution at steady state (818 ± 96 VS i 241 ± 159 mL/kg) were statistically significantly
different (p-value < 0.05) between llamas and alpacas, respectively. The elimination rate
constant and clearance of oxytetracycline tend to be higher and the elimination half-life
tends to be longer than the values found in llamas.
With LA-TM administration, absorption rate constants and peak plasma
concentrations (5.11 ± 1.61 VS 1.92 ± 0.28 ig/mL) were statistically significantly different
(p-value < 0.05) between llamas and alpacas, but the time to peak plasma oxytetracycline
concentrations (450 + 220 VS 280 + 145 mm) were similar.
Based on the data obtained, llamas and alpacas handle oxytetracycline distinctly
differently since the disposition of oxytetracycline after IV and LA-IM administration
differs significantly. In order to achieve MIC > 2 tg/mL in both animals, the proposed
dosage regimens are different. For IV dose, administering 4 mg/kg of oxytetracycline
every 24 hours to llamas will give the trough plasma concentration at steady state of 2.26
tg/rnL while administering 8 mg/kg of oxytetracycline every 12 hours will achieve the
trough plasma concentration at steady state of 2.26 jig!mL in alpacas.
With LA-TM administration, injecting 10 mg/kg of oxytetracyclineevery 60 hours
to the llama will give trough plasma concentration at steady state of 2.24 ig/mL whereas
administering LA-TM formulation with loading dose of 20 mg/kg anda maintenance dose
of 10 mg/kg every 48 hours will achieve trough plasma concentration at steadystate of
3.04 j.tg/mL in alpacas.56
Table 3.7 Comparison of recommended dosage regimens of oxytetracycline in llamas and
alpacas.
Animals Formulation Dose
(mg/kg)
Dosing interval
(h)
Cost for 5 days
($)
Llamas IV 4 24 1.60
LA-IM 10 60 2.25
Alpacas IV 8 12 3.30
LA-IM 20 (LD)
10 (MD)
48 2.00
LD = Loading dose
MD = Maintenance dose
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CHAPTER 4
PHARMACOKJNETICS OF FLORFENICOL IN ALPACAS FOLLOWING
INTRAVENOUS ADMINISTRATION
Triporn Wattananat, J. Mark Christensen, and Bradford B. Smith58
ABSTRACT
Florfenicol, a fluorinated derivative of thiamphenicol, is a widely used broad
spectrum antibiotic for the treatment of various infections in veterinary medicine.
Florfenicol has the advantages over chioramphenicol and thiamphenicol in that it shows a
broader spectrum of antibacterial activity without carrying the risk of inducing aplastic
anemia. The purpose of this study was to investigate the pharmacokinetics of florfenicol in
alpacas following intravenous administration at a single dose of 20 mg/kg body weight.
After the IV dose, the plasma concentration-time curves were best described using a two-
compartment open model with first-order elimination. The apparent volume of distribution
of the central compartment (Vc) was 0.170 ± 0.107 L/kg, while the volume of distribution
at steady state (Vss) was 0.652 ± 0.2 17 L/kg. The harmonic mean elimination half-life was
2.63 ± 0.20 hours. The total body clearance was 0.2 18 ± 0.055 L/kg/h. According to the
pharmacokinetic parameters obtained, the proper dosage regimen for alpacas is 8 mg/kg IV
every 12 hours which will achieve a trough concentration of 0.36 .ig/mL, at steady state
dosing.59
INTRODUCTION
Florfenicol is a common antimicrobial of the phenicol class of antibiotics with
chioramphenicol and thiamphenicol. Florfenicol is a structural analog of thiamphenicol in
which a hydroxyl group has been substituted with fluorine, as shown in Figure 4.1
(Prescott, 2000). Like thiamphenicol, florfenicol does not carry the risk of inducing
aplastic anemia that is associated with chloramphenicol because it lacks a nitrogroup on
the aromatic ring. It also has a broader antibacterial spectrum with activity againstsome
chloramphenicol-resistant strains of bacteria such as Escherichia coli, Klebsiella
pneumoniae, Proteus vulgaris, Salmonella typhimurium, and Staphylococcus aureus, etc.
(Neu and Fu, 1980) that can produce chloramphenicol acetyl transferase, anenzyme
responsible for plasmid-mediated bacterial resistance to chioramphenicol and
thiamphenicol (Prescott, 2000; Syriopulou etal., 1981). Because of the substitution ofa
fluorine atom for the 3-hydroxyl group, florfenicol is able to maintain its antimicrobial
activity in the presence of chloramphenicol acetyl transferase enzyme (Hoar ci' al., 1998).
The activity of florfenicol against common pathogenic bacteria is presented in Table 4.1
(Neu and Fu, 1980; Aguirre etal., l994 Marshall et al., 1996; Ayling etal., 2000a;
Prescott, 2000), while the susceptibility of resistant bacteria to florfenicol is shown in
Table 4.2 (Ho etal., 2000; Neu and Fu, 1980; Aguirre etal., 1994; Marshall etal., 1996;
Ayling et al., 2000b; Prescott, 2000).
The bacteriostatic action of florfenicol is due to its ability to inhibit bacterial
protein synthesis by irreversible binding to the SOS subunit of the bacterial ribosome and
interfering with the formation of peptides by blocking the action of peptidyl transferase
(Kapusnik etal., 1996; Prescott, 2000). This bacteriostatic effect of florfenicolcan
become bactericidal at high concentrations (Prescott, 2000).
Florfenicol has a relatively high apparent volume of distribution, 5.11 L/kg, 5.15
L/kg, 3.41 L/kg, 0.95 L/kg, and 0.77 L/kg have been reported in broiler chickens (Afifi and
EI-Sooud, 1997), Egyptian goats (Atef ci al., 2000), Muscovy ducks (El-Banna, 1998),
calves (De Craene et al., 1997), and cattle (Lobell etal., 1994), respectively.0
H NH-C-CHCl2
OON_GCCCH 20H Chioramphenico!
OHH
0
H NHC-CHCl2
H3C-S02-GCC_CH2 OH Thiamphenicol
OHH
0
H NHC-CHCl2
H3C_SO2CH2F Florfenicol
OHH
Figure 4.1 Chemical structures of chioramphenicol, thiamphenicol, and florfenicol.
The plasma protein binding of florfenicol is low. In veal calves, 22-26% of the
drug binds to plasma proteins (Adams el al., 1987) while 22.45%, 19.9%, and 18.5%
binding to plasma proteins was reported in Egyptian goats (Atefet al.,2000), Muscovy
ducks (El-Bannaetal.,1998), and broiler chickens (Afifi and El-Sooud, 1997),
respectively.
Dc Craeneetal.(1997) showed that florfenicol penetrated well into cerebrospinal
fluid well with a relative availability of 46% to plasma. Therefore, florfenicol has61
extensive distribution in tissue as its high volume of distribution and low protein binding
would suggest. In calves, 50% of the drug is eliminated unchanged in the urine (Varma et
al., 1986).
Florfenicol is solely for use in veterinary medicine. Long-term florfenicol
administration might cause reversible bone marrow suppression through its effectson
erythroid cells (Prescott, 2000). Transient diarrhea or inappetence has been reported in
cattle which usually return to normal within a few days after the end of treatment (Prescott,
2000). Local irritation at the injection site was also reported for the drug (Schering-
Plough, 1996).
Table 4.1 Susceptibility of common pathogenic bacteria to florfenicol.
Bacteria MIC (j.tg/mL)
Actinobacillus pleuropneumoniae I
Haeinophilus somnus 0,5
Pasteurella haeinolytica 1
Pasteurella multocida 0.5
Streptococcus dysgalactiae 2
Streptococcus uberis 2
Mycoplasma mycoides 2
Haemophilus influenzae 0.8
Neisseria gonorrhoeae 3.1
Serotnanas veronii 1
Fusobacteriurn mecrophoruin 0.25
Bacteroides melaninogenicus 0.2562
Table 4.2 Susceptibility of resistant bacteria to florfenicol.
Bacteria MIC (jig/mL)
Escherichia coil 4-8
Enterobacter cioacae 12.5
Klebsieiia pneumoniae 3.1
Providencia 12.5
Serratia marcescens >200
Pseudomonas aeruginosa 64-100
Salmonella typhiinuriu,n 3.1
Proteus rettgeri 12.5
Proteus vuigaris 12.5
Acinetobacter 100
Shigelia sonnei 3.1
Citrobacterfreundii 12.5
Staphylococcus aureus 3.1
Bacteroides melaninogenicus 12.5
Salmonella typhi 3.1
Mycoplasina bovis 16
Vibrio spp. 25
Pharmacokinetic studies of florfenicol have been conducted in some animal
species such as goats, dairy cows, cattle, calves, ducks, chicken, pigs, etc. The
pharmacokinetic parameters reported in those animals are listed in Table 4.3.Table 4.3 Pharmacokinetic parameters of florfenicol in some animal species.
Animals
Dose (mg/kg)
Route
Parameters
Broiler chickens'
30
IV
Broilerchickens2
30
IV
Muscovyducks3
30
IV
Pigs4
20
IV
Calves5
20
IV
X1(h') 3.84±0.12 2.10 ±0.18 5.60±2.21 4.17 ±4.04
X (h') 0.24±0.12 0.10±0.01 0.19±0.01 0.23±0.06
t,,(h) 0.18±0.01 0.326±0.004 0.64±0.39 0.38±0.32
t,2(h) 2.89±0.14 2.68±0.45 7.18±0.14 2.63±0.51 3.18±1.01
MRT(h) 3.92± 1.34
Vss(L/kg) 5.11 ±0.69 1.15 ±0.41 5.15 ±0.10 0.95 ±0.07 0.95 ±0.20
Vc (L/kg) 1.46±0.08 0.89±0.16 1.59±0.01 1.17±0.32
CLT(L/kg/h) 1.61±0.14 0.73±0.12 0.61±0.01 0.31±0.02 0.22±0.05
1(Afifi et at.,1997); 2=(Shenetal.,2002) 3=(El-Bannaet at.,1998); 4=(Liuetal.,2003); 5=(De Craeneet at.,1997)
L.JTable 4.3 (Continued)
Animals Vealcalves6 Vealcalves7 Cattle8 Lactatingcows9 Egyptian goats'°
Dose (mg/kg) 11 22 20 20 20
Route IV IV IV IV IV
Parameters
X1(h') 5.60±2.21 6.55±1.76 15.4**
(4.3 8-30.7)
X,(h1) 0.19±0.01 0.24±0.04 1.50** 0.23±0.03
(0.94-2.32)
(h) 0.13** 0.l0 0.17±0.02
(4.48-16.3) (0.08-0.17)
t112(h) 3.71** 2.87** 2.65* 2.93* 0.94±0.05
(3.46-4.11) (2.30-3.40) (2.42-3.03) (3.0±0.37)
MRT(h) 33** 2.15±0.167 1.04±0.06
(3.1-4.1)
Vss (L/kg) 0.87** 0.75** Ø77** 0.35±0.10 3.41±0.30
(0.74-1.03) (0.65-0.80) (0.68-0.85)
Vc (L/kg) 0.27**
(0.18-0.47)
CLT(L/kg/h) 0.17** 0.17** 0.23** 0.16 ±0.04 3.31±0.33
(0.15-0.18) (0.17-0.24) (0.19-0.26)
* = harmonicmean
**= median value (range)
6=(Adams etal., 1987); 7=(Varma etal., 1986); 8=(Lobe11 et al., 1994); 9=(Soback et al., 1995); 10(Atefet al., 2000);Table 4.3 (Continued)
Animals
Dose (mg/kg)
Route
Parameters
Goats"
20
IV
Atlanticsalmon'2
10
IV
Loggerhead sea turtles'3
20
IV
Humanh4*
500 mg
IV
X, (h') 0.17 13.9
X (h') 0.08 -
0.09-0.35
t,2, (h) 0.27±0.01 0.05
t,12(h) 2.61±0.15 14.7 2-7.8 2.1
MRT(h) 3.18±0.23
Vss(L/kg) 1.68±0.11 1.32 10.5-60
Vc (L/kg)
CLT(L/kg/h) 0.55±0.07 3.6-6.3
* =thiamphenicol
1 l=(Atefet al.,2001); 12=(Horsberg, 1996); 13=(Stamperet al.,2003); 14=(Ferrari, 1984)66
Abbreviations used in Table 4.3:
= distribution rate constant,t112= distribution half-life, Xz = elimination rate constant,
t1,2= elimination half-life, MRT = mean residence time,CLT= total body clearance, Vss
= apparent volume of drug distribution at steady state, and Vc = apparent volume of the
central compartment.
Information on the pharmacokinetics of florfenicol in alpacas is speculative so the
appropriate dosage regimen of florfenicol in alpacas has not been defined yet. A dose of
20 mg/kg body weight was selected for the florfenicol pharmacokinetic study in alpacas
based on the recommended dose for cattle. The purpose of this study was to investigate the
pharmacokinetics of florfenicol in alpacas following intravenous administration. Based on
the pharmacokinetic parameters obtained, the proper dosing regimen can be developed in
order to improve the overall health and drug treatment of alpacas.
MATERIALS AND METHODS
Drugs and chemicals:
Nuflor', 300 mg florfenicol/mL (Schering-Plough Animal Health Corp,
Kenilworth, New Jersy, USA) was used for intravenous injection. Ethyl paraben was
obtained from SIGMA Chemical Co. (St. Louis, Missouri, USA). Acetonitrile (HPLC
grade) and ethyl acetate (HPLC grade) were obtained from Fisher Scientific (Fair Lawn,
New Jersy, USA). Monobasic potassium phosphate and sodium hydroxide were obtained
from SPECTRUM (New Brunswick, New Jersy, USA).
Animals:
Six healthy adult alpacas, three females and three gelded males in the Veterinary
Medicine Animal Isolation Laboratory at Oregon State University, weighing between 59.6-
71 .9 kg, age 4-8 years, were used in the study. All animals received a routine checkup67
including vaccination and deworming prior to the study. Routine health treatments were
completed at least two weeks prior to the start of the study. Grass hay and waterwere
availablead Iibitu,n.
Administration of drugs and sampling protocol:
Nuflor was administered to the animals via jugular vein as a single injection ata
dose of 20 mg/kg bodyweight. Blood samples were collected via the jugular vein
immediately prior to drug administration and at 10, 20, 30 minutes and 1, 1.5, 2, 3,4, 6, 8,
12, 24 hours after IV administration. Before taking a blood sample, 8 mL of bloodwas
drawn and discarded. After each 10 mL blood sample was collected, the catheterwas
flushed with heparinized normal saline. All blood samples were transferred to evacuated
tubes coated with 15.0mg EDTA powder and mixed gently. Plasmawas separated by
centrifugation at 1,500 x g for 15 minutes and stored at -20°C until assayed.
Analytical method:
The plasma concentrations of florfenicol were measured by High Perfon-nance
Liquid Chromatography (HPLC) using a modified technique of Lobellet al.(1994). The
HPLC system consisted of an autosampler (WISP model 712, Waters, Division of
Millipore, Milford, MA, USA), a pump (model 590, Waters, Division of Millipore,
Milford, MA, USA), a variable wavelength ultraviolet absorption detector (Spectroflow
model 783, Applied Biosystems, Ramsey, NJ, USA), and an integrator (model CR 501,
Chromatopac, Shimadzu Scientific Instruments, Inc., Columbia, MD, USA).
A sample of plasma (500 1.iL) was added to each test tube containing the internal
standard, 1.6 jig of ethyl paraben, and was mixed for 30 seconds using vortex mixer. Half
a milliliter of 0.2 M phosphate buffer (pH 7.0) was then added to each test tube and
vortexed for 10 minutes. Two milliliters of ethyl acetate were added and the contents of
the tubes were mixed by end-over-end rotation for 10 minutes. Theupper ethyl acetate
phase of each sample was transferred to another glass test tube and evaporated under
vacuum at 40°C until complete dryness. The samples were reconstituted with 0.5 ml. of
HPLC mobile phase composed of 40% acetonitrile and 60% deionized water. Samples(100 j.iL) of the solutions were injected ontoC18column (Phenomenex, Torrance, CA,
USA) and scanned by the ultraviolet detector whose wavelength was set at 229 nm.
Calibration curves for the quantification of florfenicol in alpaca plasma were
obtained by plotting the ratio of peak areas of florfenicol and ethyl paraben against the
concentrations of florfenicol prepared as standard solutions. The calibration curves were
determined to be linear. Correlation coefficients of calibration curves were by linear
regression analysis greater than 0.999. The concentrations of florfenicol in alpaca plasma
samples were calculated from the calibration curve using inverse prediction.
The overall percent coefficient of variation (% CV) of the florfenicol assay was
7.98%. The % CV of florfenicol concentration in prepared standard solutions is shown in
Table 4.4. The limit of quantification was 0.19 ig/mL.
Table 4.4 The percent coefficient of variation (%CV) of florfenicol concentration in
prepared standard solutions.
Actual conc.
(ig/mL)
Average of predicted
conc. (igImL)
SD %theoretical
cone.
%CV
0.19 0.169 0.072 88.02 42.6
0.48 0.514 0.088 107.1 17.1
0.96 1.128 0.100 117.5 8.87
1.92 1.870 0.126 97.40 6.74
3.84 3.533 0.154 92.01 4.35
4.80 4.364 0.056 90.92 1.28
9.60 9.245 0.167 96.30 1.81
19.2 18.84 1.351 98.13 7.17
28.8 30.27 1.179 105.1 3.89
48.0 48.25 0.821 99.16 1.70
57.6 58.10 0.500 100.4 0.86
96.0 95.34 0.474 99.66 0.50
Grand mean of% theoretical cone. = 99.3
Grand SD of mean % theoretical conc. = 7.93
Overall %CV = 7.9869
Pharmacokinetic analysis:
The plasma concentration-time curves of florfenicol following IV administration
for each individual alpaca were fitted by both compartmental and noncompartmental
approaches with WinNonlin Professional Version 3.2 software (Pharsight Corporation,
Mountain View, California, USA) using a weighting factor of 1/plasma concentration. The
optimum number of first-order rate processes in the predictive equation was selected on the
basis of the minimal Akaike's information criterion (Wagner, 1993; Yamaoka et al., 1978).
A linear two-compartment open model best described florfenicol plasma concentration-
time profiles after IV administration.
For compartmental analysis, the phannacokinetic parameters were calculated from
the equation best describing the plasma concentration-time profiles. The area under the
curve (AUC0) was calculated from the coefficients and exponential constants of the
equation explaining the data.
Cp=Cje1*o) (1)
AUC0= (2)
where Cp is the plasma concentration, X is the exponential constant, C, is the coefficient,
and n is the number of exponential terms in the equation.
The total body clearance (CLT) was calculated according to the following equation.
CL =
A
MRT is the mean residence time and is equal to
(3)
MRT
AUMC0
(4)
AUC0
AUMC000isthe area under first moment versus time curve, and was calculated from
AUMCQ= (5)
The apparent volume of distribution at steady state (Vss) was calculated according to
Vss=CLxMRT (6)Half-lives were calculated according to
70
0.693
= (7)
For noncompartmental analysis, the MRT and terminal half-live were calculated as
stated above. The area under the curve (AUC0) and the area under the first moment curve
(AUMC0) were calculated by the trapezoidal rule up to the last sampling time point
(AUC0) and extrapolated to infinity (AUC) using the equation
AUC1=
Az
(8)
t*CtCt
AUMC1J
Az+
(9)
Therefore, AUC0= AUCO + AUC (10)
t*Ct Ct
and AUMC0= AUMCO ++- (11)
Az Az2
The terminal volume of distribution (Vz) was calculated by the following equation.
(12)
RESULTS
The plasma concentration-time curves were individually fitted following IV
administration. Table 4.5 showed the plasma concentrations of florfenicol in each alpaca
after IV administration after being given a single dose of 20 mg/kg body weight. Also
listed in Table 4.5 are the average florfenicol concentrations with standard deviation at
each time point. The semilogarithmic plot of individual plasma concentrations of
florfenicol after IV administration are presented in Figure 4.2, while the mean plasma
concentration of florfenicol for six alpacas following IV administration along with the
standard deviations are depicted in Figure 4.3.71
The plasma concentration-time profile after IV administration showed declining
florfenicol plasma concentrations that followed a bi-exponential manner, as demonstrated
in Figure 4.4, according to the equation
Cp + (13)
where Cp is the plasma concentration of florfenicol at time t,C1andC2are the coefficients,
and 2andA.2are the exponential constants for the biexponential equation describing the
florfenicol plasma concentration-time curve.
Pharmacokinetic parameters of florfenicol after IV administration obtained from
compartmental and noncompartmental analysis are summarized in Tables 4.5 and 4.6,
respectively.Table 4.5 Plasma concentrations of florfenicol (tg/mL) in six alpacas at each sampling time point after 20 mg/kg IV administration.
Time Plasma florfenicol concentrations (j.ig/mL)
(mm) Alpaca 1 Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
10 91.1404 40.0395 85.6813 72.0959 40.4080 66.1389 65.9173 21.8423
20 32.0340 21.8530 30.8233 41.6416 24.2196 33.0037 30.5959 7.0288
30 24.1463 19.6291 25.3206 36.1268 18.9413
-
30.3027 25.7445 6.5572
60 13.5351 14.2844 19.8864 30.3027 14.5334 22.1140 19.1093 6.4840
90 11.3168 11.8977 16.2657 18.4044 10.2197 20.2799 14.7307 4.1636
120 10.6930 10.0460 11.0714 12.9738 7.4568 14.9922 11.2055 2.5747
180 7.9854 6.4433 8.5209 8.1346 4.4362 9.9332 7.4756 1.9011
240 5.4687 5.1026 4.0825 7.0334 2.6649 3.9844 4.7227 1.4986
360 2.8625 2.4499 2.5346 3.5247 1.9787 2.8871 2.7063 0.5199
480 1.9523 1.3660 1.7290 2.2148 1.0252 1.4530 1.6234 0.4295
720 09891 0.8971 0.8608 0.7612 0.6349 1.0532 0.8660 0.1520
1440 0.2044 0.2565 0.3401 0.3101 0.2901 0.4046 0.3847 0.1656-J
E
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Figure 4.2 Semilogarithmic plot of individual florfenicol plasma concentration-time curves
in alpacas after a 20 mg/kg single dose IV administration.
100
-j
E
0)10 U
E
0
4-
C
a)U
C
00
0.1!
0 200 400 600 800 1000 1200 1400 1600
Time (mm)
Figure 4.3 Semilogarithmic plot of mean florfenicol plasma concentration-time curve along
with standard deviations in alpacas after a single dose of 20 mg/kg was administered
intravenously.Table 4.6 Pharmacokinetic parameters of florfenicol in alpacas after 20 mg/kg IV administration using compartmental analysis.
Parameters Alpaca I Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
Ct(tg/mL) 291 67.2 313 79.6 46.9 130 155 118
C2(ig/mL) 17.4 16.1 21.3 25.3 12.6 23.5 19.4 4.82
2.1(mm') 0.137 0.102 0.157 0.062 0.050 0.110 0.103 0.042
X2(min') 0.0043 0.0040 0.0049 0.0047 0.0044 0.0042 0.0044 0.0003
tl/,xl(min) 5.06 6.79 4.41 11.2 13.9 6.30 6.73* 375
t,i2,2(min) 161 173 141 147 158 165 158* 11.7
MRT(min) 154 218 142 176 178 199 178 28.0
CLT
(mL/kg/min)
3.25 4.24 3.15 2.99 5.22 2.94 3.63 0.91
AUC
(jigmin/mL)
6151 4715 6358 6677 3830 6799 5755 1204
Vc(mL/kg) 64.9 240 59.8 191 336 130 170 107
Vss(mL/kg) 501 925 447 527 930 585 652 217
* = harmonicmeanTable 4.7 Pharnrncokinetic parameters of florfenicol in alpacas after 20 mg/kg IV administrationusing noncompartmental analysis.
Parameters Alpaca 1 Alpaca 2 Alpaca 3 Alpaca 4 Alpaca 5 Alpaca 6 Average SD
2z (mm') 0.0037 0.0037 0.0052 0.0039 0.0040 0.0036 0.0040 0.0006
tl/2,?Z(min) 186 189 133 178 175 191 173* 21.7
MRT(min) 180 248 172 203 222 243 211 31.8
AUC
(jigminlmL)
6476 4971 6524 7215 3939 7117 6040 1306
CLz
(mL/kg/min)
3.09 4.02 3.07 2.77 5.08 2.81 3.47 0.91
Vz(mL/kg) 835 1087 590 711 1269 781 879 253
* = harmonicmean76
DISCUSSIONS AND CONCLUSION
The pharmacokinetic behavior of florfenicol in alpacas after IV administration of a
single dose of 20 mg/kg was best described by a two-compartment model on the basis of
minimal AIC. This conclusion is in agreement with the results of previous studies carried
out on some animal species such as broiler chickens (Afifi et al., 1997 andShenet al.,
2002), Muscovy ducks (El-Banna et at., 1998), and veal calves (Varma etal., 1986). A
three-compartment open model gave the best fit in cattle (Lobell et at., 1994). A rapid
distribution phase occurred in alpacas with a harmonic mean half-life of 6.73 ± 3.75 mm
(0.11 ± 0.06 h) while half-lives of 10.25 ± 0.94, 10.85 ± 1.96, 22.8 ± 1.96, and 38.4 ± 23.4
mm were reported in Egyptian goats (Atef et at., 2000), broiler chickens (Afifi et at.,
1997), holestein calves (Dc Craene et at., 1997), and pigs (Liu et at., 2003), respectively.
In alpacas, the harmonic mean elimination half-life of florfenicol was 158 ± 11.7 mm (2.63
± 0.20 h) compared to 2.65 h in cattle (Lobell et at., 1994), and 2.93 h in lactating cows
(Soback et al., 1995) and 2.87 h in veal calves (Varma et at., 1986).
For alpacas, the apparent volume of distribution of the central compartment (Vc)
was 0.17 ± 0.11 L/kg whereas 1.17 ± 0.32 L/kg, 1.46 ± 0.08 L/kg and 1.59 ± 0.01 L/kg
were reported in pigs (Liu et at., 2003), broiler chickens (Afifi etal., 1997) and Muscovy
ducks (El-Banna et at., 1998), respectively. The apparent volume of distribution at steady
state (Vss) in alpaca was 0.65 ± 0.22 L/kg, while 0.35 ± 0.10 L/kg, 5.11 ± 0.69 L/kg, and
5.15 ± 0.10 L/kg were found in lactating cows (Soback etal., 1995), broiler chickens (Afifi
etal., 1997), and Muscovy ducks (El-Banna et at., 1998), respectively.
The total body clearance of 3.63 ± 0.91 mL/kg/min (0.22 ± 0.05 L/kg/h) was
similar to reported value of 0.22 ± 0.05 L/kg/h in calves (De Craene et at., 1997) and 0.23
L/kg/h in cattle (Lobell etal., 1994) compared to 3.31 ± 0.33 and 0.31 ± 0.02 L/kg/h
reported values in Egyptian goats (Atefet al., 2000), and pigs (Liu et at., 2003),
respectively.
Florfenicol has a broad spectrum of activity against a number of common
pathogenic bacteria. The minimum inhibitory concentration (MIC) of florfenicol for
Pasteure!!a muttocida and Pasteuretta hemotytica, which are primary pathogenic bacteria77
causing bovine shipping fever, range from 0.25-5 tg/mL (Varma et al., 1986), whereas the
MIC for Haemoph i/us somnus, an important pathogen involving bacterial meningitis, was
0.25 tg/rn1. (De Craene et al., 1997).
It is desirable to maintain florfenicol plasma concentrations above the MIC of 0.25
j.ig/rnL during antibiotic therapy to eradicate infection. Using superposition method, it was
determined that a 8 mg/kg dose delivered by IV injection should be given every 12 hours.
The superposition method determined that a steady state trough concentration of 0.36
jig/mL will be achieved for IV administration.
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CHAPTER 5
COMPARATIVE PHARMACOKINETICS OF FLORFENICOL IN LLAMAS AND
ALPACAS FOLLOWING INTRAVENOUS ADMINISTRATION
Triporn Wattananat, Mutasim A1-Ghazawi, J. Mark Christensen, and
Bradford B. SmithABSTRACT
This chapter compares the pharmacokinetics of florfenicol in alpacas following a
single dose of 20 mg/kg body weight given by intravenous injection administration and
with the results previously obtained in llamas. After IV administration, a two-
compartment open model best described the plasma concentration-time profiles of both
llamas and alpacas. There were no significant differences between these two animals in
any of the pharmacokinetic parameters. Since the disposition of florfenicol in llamas and
alpacas is not statistically significantly different, it can be concluded that they have similar
disposition kinetics of florfenicol.INTRODUCTION
Llamas and alpacas are members of South American camelids (SACs). They were
introduced into North America in the nineteenth century as zoo animals (Fowler, 1998).
The llama and the alpaca have become economically important animals of the four SACs
(llama, alpaca, guanaco, and vicuna) (Smith, 1998).
Bacterial infections are common problems in llamas and alpacas (Fowler, 1998).
The symptoms of illness rarely show until the infection has extensively progressed because
they are very stoic animals (Burt, 1991). Since the information on the pharmacokinetics of
antimicrobials in llamas and alpacas is very limited, the dosage regimen of any
antimicrobials in these two animals has not been defined yet.
At present there are no drugs approved for use in the llama and the alpaca (Smith,
1998). Drug dosing for the treatment of bacterial infections are frequently based on dosing
used in sheep and cattle (ruminants). In fact, camelids and ruminants evolutionally
separated from each other 30-40 million years ago (Fowler, 1998). Drug dosing across
species is not appropriate because different animal species might handle the same drug in a
different manner.
The objective of this study is to compare the pharmacokinetics of florfenicol in the
alpaca with results previously obtained in the llama (Al-Ghazawi, 1998) and determine if
drug disposition between the two animals is similar.
RESULTS
The plasma concentration-time profiles of florfenicol following a single dose (20
mg/kg) IV administration in both llamas and alpacas were best fitted to a two-compartment
open model. The comparison of mean plasma concentrations versus time along with
standard deviations after IV dose in both animals is shown in Table 5.1 and Figure 5.1.
Noncompartmental analysis of the plasma concentration-time curves of florfenicol
in llamas and alpacas after a 20 mg/kg IV dose was also performed. The meanpharmacokinetic parameters (mean ± SD) for llamas and alpacas following IV
administration obtained from compartmental and noncompartmental analysis are listed in
Tables 5.2 and 5.3, respectively. The Student's t-test was used to determine significant
differences (p-value <0.05) between pharmacokinetic parameters and the results are also
shown in Tables 5.2 and 5.3, respectively.
Table 5.1 Comparison of florfenicol plasma concentrations (mean ± SD, j.tg/mL) in llamas
and alpacas after a single dose (20 mg/kg) IV administration.
Time (mm) Llamas Alpacas
10 61.51±10.1 65.92±21.8
20 29.54±5.84 30.60±7.03
30 24.79±5.32 25.75±6.56
60 16.32±4.39 19.11+6.48
90 11.15±2.58 14.73±4.16
120 8.83±2.28 11.21±2.57
180 6.68± 1.95 7.58± 1.90
240 4.09± 1.55 4.72± 1.50
360 2.36±1.38 2.71±0.52
480 1.30±0.70 1.62±0.43
720 0.75±0.69 0.87±0.15
1440 0.32±0.39 0.38±0.17-J
E
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Figure 5.1 Semilogarithmic plot of average plasma concentration-time curves of florfenicol
in llamas and alpacas after IV administration at a single dose of 20 mg/kg.Table 5.2 Pharmacokinetic parameters of florfenicol (mean ± SD) after a single dose (20mg/kg) IV administration using compartmental
analysis.
Parameters Llamas Alpacas Level of
significance
p-value Number of subjects
required to be statistical
significant different
C1(.ig/mL) 107±56.1 155±118 NS 0.195 30
C2(jtg/mL) 15.4±4.57 19.4±4.82 NS 0.088 11
X1(min') 0.082 ± 0.030 0.103 ± 0.042 NS 0.173 24
X2 (mind) 0.005 ± 0.002 0.004 ± 0.0003 NS 0.129 115
t112,1(mm) 8.47* ± 3.89 6.73* ± 3.75 NS 0.225 39
tl/2?2(min) 147*±65.3 158*± 11.7 NS >0.25 145
MRT(min) 174± 73.6 178±28.0 NS >0.25 1550
CLT(mL/kg/min) 4.04±1.05 3.63±0.91 NS 0.244 46
Vc(mL/kg) 185 ±59.3 170± 107 NS >0.25 266
Vss(mL/kg) 706± 144 652±217 NS >0.25 93
AUC(ig.min/mL) 4855± 1081 5755± 1204 NS 0.100 13
*harmonic meanTable 5.3 Pharmacokinetic parameters of florfenicol (mean + SD) after a single dose (20 mg/kg) IV administration using
noncompartmental analysis.
Parameters Llamas Alpacas Level of
significance
p-value Number of subjects
required to be statistical
significant different
2z (mm') 0.004±0.002 0.004±0.001 NS >0.25 232
t112(min) 166*±90.6 173*±21.7 NS >0.25 318
CLz (mL/kg/min) 4.14±1.20 3.47 ± 0.91 NS 0.15 1 21
Vz(mL/kg) 965 ±211 879±253 NS >0.25 55
MRT(min) 186±79 211±32 NS 0.245 38
AUC (.tgmin/mL) 5135 ± 1567 6040 ± 1306 NS 0.151 18
*= harmonic meanDISCUSSIONS AND CONCLUSION
There were no significant differences between llamas and alpacas in all of the
florfenicol pharmacokinetic parameters. According to noncompartmental analysis,
elimination rate constant (0.0042 ± 0.00 16 VS 0.0040 + 0.0006 mm1), harmonic mean of
elimination half-life (166 ± 90.6 VS 173 + 21.7 mm), terminal clearance (4.14 ± 1.20 VS
3.47 ± 0.91 mL/kg/min), terminal volume of distribution (965 + 211 VS 879 ± 253 mL/kg),
mean residence time (186 ± 79 VS 211 ± 32 mm), and area under the curve (5135 ± 1567
VS 6040 ± 1306 jig.min/mL) of llamas and alpacas were not statistically significant
different. Based on the data obtained, llamas and alpacas handle florfenicol similarly since
the disposition of florfenicol after IV administration is similar.
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PHARMACOKINETICS OF CLORSULON IN LLAMAS AFTER ORAL
ADMINISTRATION
Triporn Wattananat, Bradford B. Smith, and J. Mark ChristensenABSTRACT
Clorsulon is a narrow-spectrum anthelmintic agent which possesses potent
fasciolicidal activity. The purpose of this study was to investigate the pharmacokinetics of
clorsulon in llamas following oral administration of clorsulon at a single dose of 14 mg/kg
of body weight. After the oral dose, the plasma concentration-time curves were best
described using a one-compartment open model with first-order input and first-order
output. The first-order absorption rate constant (Ka) was 0.184 ± 0.135hour1whereas the
first-order elimination rate constant was 0.0 15 ± 0.005 hour'. The harmonic mean
elimination half-life was 39.2 hours. The maximum plasma concentration(Crnax) was
0.706 ± 0.129 j.ig/mL and the time to reach maximum plasma concentration (tmax) was 24
hours.91
INTRODUCTION
Various parasitic infections in llamas have been reported in the literature. Those
diseases included trypanomiasis, toxoplasmosis, coccidiasis, fascioliasis, giardiasis, etc., as
listed in Table 6.1 (Cheney and AlIen, 1989; Rickard and Bishop, 1991; Rickard, 1994;
Fowler, 1998).
Hepatic fascioliasis, or liver fluke infection, is an important problem that causes
liver damage and death in llamas (Smith, 1998). Both acute and chronic fascioliasis have
been reported (Rickard and Bishop, 1991; Rickard, 1994) but the chronic form is more
often seen (Fowler, 1998). Fluke-infected animals will first show clinical signs of
anorexia, weight loss, pale mucus membranes, and ill thrift, followed by chronic stasis of
the bile due to bile duct obstructions by flukes. Thereafter, hepatic fibrosis occurs which
causes intrahepatic hypertension. Also, adult flukes living in bile ducts suck the blood
causing anemia (Fowler, 1998).
The liver fluke,Fasciola hepatica,matures in bile ducts of the llamas and their
eggs pass down the bile ducts and are excreted with the feces. The eggs fall into water and
the ciliated miracidium develop 10-12 days later. Then, the miracidium infect the snail
which acts as the intermediate host of the liver fluke. Miracidium mature to become a
cercaria in snails in 4.5-7 weeks. The cercaria leaves the snail and attaches to a plant and
becomes a metacercaria which is the infective stage for llamas (Fowler, 1998). Llamas can
get fluke infection if they graze in a pasture contaminated with metacercaria (Cheney and
Allen, 1989). When metacercaria are ingested, immature flukes will be released into
duodenum. They penetrate the intestinal wall and migrate to the liver and mature in the
bile ducts (Fowler, 1998).
Presently, the only anthelmintic agents effective against liver flukes are clorsulon
and albendazole (Rickard, 1994; Rew and Mckenzie, 2000).
Clorsulon (4-amino-6-trichloroethenylbenzene- 1,3 -disulfonamide) is characterized
as a narrow-spectrum anthelmintic drug in the benzenedisulfonamide family (Rew and
Mckenzie, 2000). The chemical structure of clorsulon is shown in Figure 6.1 (O'Neilet
al.,2001).Table 6.1 Parasitism in llamas.
Disease Parasites Signs and Symptoms
Trypanomiasis Tiypanosoma brucei Fever, depression, weakness, and edema
Trypanosoma evansi
Toxoplasmosis Toxoplasma gondii Abortion
Coccidiosis Eimeria lamae Enteritis and diarrhea
Eimeria alpacae
Eimeria punoensis
Ei,neria nacusan iensis
Sarcocystiasis Sarcocystis aucheniae Acute febrile disease resulting in abortion, mild myositis with
Sarcocystis tilopodi myalgia
Giardiasis Giadiasia spp. Soft stool, diarrhea
Fascioliasis Fasciola hepatica Chronic stasis of the bile, hepatic fibrosis, elevation of
intrahepatic blood pressure
Hydatid disease Echinococcus granulosus Malfunction of organ
Monieziasis Moniezia expansa Diarrhea and unthriftiness
Mon iezia ben edeni
Cephenemyia Cephenemyia spp. Sneezing, coughing, nasal discharge, and difficult breathingTable 6.1 (Continued)
Disease Parasites Signs and Symptoms
Encephalomalacia Parelaphostrongylus tenuis Local hemorrhage, head tilting, arching of the neck,
incoordination, difficulty in getting up, and a gradual weight
loss over several weeks
Sarcoptic mange Sarcoptes spp. Scaly, crusty lesion, loss of wool, intense pruritic reaction that
leads to self trauma and excoriation
Chorioptic mange Chorioptes spp. Mild pruritus, lesions start on the feet and at the base of the
tail, then spread to other parts of the body
Tick paralysis Derrmacentor ticks Weakening of the hind legs, unsteady gait, knuckling, and
ataxia. The animal has difficulty chewing, swallowing, and
breathingCl
H2
H2NO2SSO2NH2
Figure 6.1 Chemical structure of clorsulon
Clorsulon is effective against adult liver flukes (>15 weeks) but have little activity
against immature flukes (6- 8 weeks) (Prichard, 1986; Plumb, 1995; and Zimmerman et at.,
1986). The fasciolicidal activity of clorsulon has been studied in experimentally fluke-
infected rats, sheep, goats, and calves and in naturally and experimentally fluke-infected
cattle and sheep. In rats, a single oral dose of clorsulon from 12.5 to 100 mg/kg was 84-
100% effective against mature flukes while the efficacy reduced to 78% when clorsulon
was given to the rats at a single dose of 6.25 mg/kg (Schulman et at., 1979). In sheep, the
efficacy of clorsulon against Fasciola hepatica at the oral dose of 7 mg/kg body weight
was reported to be 90-100% for mature flukes (Ostlind et at., 1977; Fairweather and Boray,
1999), whereas Rehbein and Visser (1999) showed that 2 mg/kg of clorsulon administered
subcutaneously killed 99% of adult flukes. Coles and Stafford (2001) reported an efficacy
of 74 % in the treatment of fluke-infected lambs given 2 mg/kg clorsulon subcutaneously.
hi cattle, the efficacy of clorsulon against mature liver flukes at the oral dose of 7 mg/kg of
body weight were reported to be 91-100% (Yazwinski et at., 1985; Courtney et at., 1985;
Kilgore et at., 1985; Zimmerman et at., 1986). Malone et at. (1990) showed that the
higher dose of clorsulon (35 mg/kg) was required to kill 99% of immature flukes in calves.
In goats, clorsulon was 98-100 % effective against adult flukes when it was administered at
a single oral dose of 7-15 mg/kg of body weight (Sundlof et at., 1991).
The efficacy of clorsulon against other flukes has also been investigated. The drug
is also effective against Fasciotoides magna in white-tailed deer (Foreyt and Drawe, 1985)95
but it is not as effective against Fascioloidesinagnaas it is against Fasciola hepatica in
cattle and sheep after being given the equivalent single oral doses of 7 mg/kg of body
weight (Foreyt, 1988). Clorsulon also showed activity against Echinostoma caproni in
ICR mice (Maurer et at., 1996) but has poor efficacy against paraphistomes (Courtney et
al., 1985; Malone et al., 1984, 1990) and has no effect on other parasites (Rew and
Mckenzie, 2000).
The fasciolicidal activity of clorsulon is due to its ability to stop energy generation
in the flukes via glucose metabolism by inhibition of two enzymes, phosphoglyceromutase
and phosphoglycerate kinase (Schulman and Valentino, 1980; Martin, 1997; Fairweather
and Boray, 1999; Rew and Mckenzie, 2000). The flukes die because clorsulon prevents its
main source of metabolic energy to be generated.
Clorsulon is a very safe anthelmintic drug. The acute toxicity of the drug has been
evaluated in mice, rats and sheep. In mice, theLD50was 761 mg/kg intraperitoneally and
more than 10,000 mg/kg orally, whereas an oral dose up to 10,000 mg/kg had no toxic
effect in rats (Ostlind et at., 1977). In sheep, doses up to 400 mg/kg have not produced
toxicity (Plumb, 1995).
Lankas and Peter (1992) reported that clorsulon increased the pH and altered the
electrolyte composition of urine in rats, which relates to the weak carbonic anhydrase
inhibitory activity of the drug as reported by Chiu et al. (1985). This enzyme inhibitory
effect which increases urinary pH and alter electrolyte excretion might cause urothelial cell
hyperplasia in rats.
Clorsulon is available in suspension formulations for oral use or injectable form for
subcutaneous administrations and also in combination with ivermectin as a product
effective against nematodes, arthropods, and flukes (Rew and Mckenzie., 2000).
Clorsulon was approved by the US Food and Drug Administration for the
treatment of liver flukes in cattle at the recommended dose of 7 mg/kg (Sundlof and
Whitlock., 1992) but has not been approved yet in sheep or llamas.
Pharmacokinetic studies of clorsulon have been conducted in some animal species
such as sheep, goats, and rats. The pharmacokinetic parameters reported in these animals
are listed in Table 6.2.Table 6.2 Pharmacokinetic parameters of clorsulon in some animal species.
Animals
Dose (mg/kg)
Route
Parameters
Sheep'
7
IV
Sheep'
7
oral
Goats'
7
IV
Goats'
7
oral
Rats2
5
oral
X, (h') 5.74±1.95 4.35±1.85
X2(h') 0.177±0.037 0.289±0.166
23(h') 0.044±0.0 15 0.073±0.048 0.054-0.065
(h) 0.12* 0.196*
t,22 (h) 393* 2.41*
tJ/2,X3 (h) 15.80* 27.86* 10.00* 22.40*
MRT(h) 11.5±2.8 34.8±5.0 6.8±2.8 29.4±8.5
tniax(h) 15.2±5.1 13.9±7.3 2-4
MAT (h) 6.89±4.28 22.8±8.8
Vss (L/kg) 0.567±0.283 0.520±0.259
Vc(L/kg) 0.151±0.034 0.135±0.051
CLT(L/kg/h) 0.05 1±0.018 0.080±0.025
F (%) 60.2±0.26 55.3±21.2
* = harmonic mean
1= (Sundlof and Whitlock, 1992); 2= (Schulman et al., 1979)Abbreviations used in Table 6.2:
X1= rapid distribution rate constant, X2= slower distribution rate constant, Xelimination
rate constant, Ka= absorption rate constant,t1/? M= rapid distribution phase half-life,t12x
= slower distribution phase half-life, t112,= elimination half-life sorption half-life,t1/2 Ka =
absorption half-life, MRT = mean residence time, MAT = mean absorption time,CLT =
total body clearance, t,, = time when maximum concentration was obtained, Vss =
apparent volume of drug distribution at steady state, Vc = apparent volume of the central
compartment, and F = bioavailability.
Information on the pharmacokinetics of clorsulon in llamas is speculative based on
information available from the cattle and sheep so the appropriate dosage regimen of
clorsulon in llamas has not been defined yet. The purpose of this study was to investigate
the pharmacokinetics of clorsulon in llamas following oral administration.
MATERIALS AND METHODS
Drugs and chemicals:
Curatrem®, 85mg clorsulonlmL (Merck Sharp & Dohme, Rahway, New Jersy,
USA) was used for oral administration. Ethyl paraben was obtained from SIGMA
Chemical Co. (St. Louis, Missouri, USA). Acetonitrile (HPLC grade), n-hexane (HPLC
grade), and ethyl acetate (HPLC grade) were obtained from Fisher Scientific (Fair Lawn,
New Jersy, USA). Monobasic potassium phosphate and sodium hydroxide were obtained
from SPECTRUM (New Brunswick, New Jersy, USA).
Animals:
Five healthy adult llamas in the Veterinary Medicine Animal Isolation Laboratory
at Oregon State University, weighing between 88.6-161.8 kg were used in the study. All
animals received a routine checkup including vaccination and deworming prior to the
study. Routine health treatments were completed at least two weeks before the start of thestudy. Grass hay and water were availablead libitu,n.
Administration of drugs and sampling protocol:
Curatrem®was administered orally to the animals via stomach tube at a single dose
of 14mg/kg bodyweight. Blood samples were collected via jugular vein catheters before
drug administration and at 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, and 72 hours after drug
administration. Before taking the next sample, 8 mL of blood was drawn from the catheter
extension and discarded to remove any of the heparinized saline flush of the previous
blood sample, ensuring a proper blood sample was drawn. After each blood sample was
collected, the catheter was flushed with heparinized normal saline. All blood samples were
transferred to evacuated tubes coated with 15.0 mg EDTA powder and mixed gently.
Plasma was separated by centrifugation at 1,500 x g for 15 minutes and stored at -20°C
until assayed.
Analytical method:
The plasma concentrations of clorsulon were measured by High Performance
Liquid Chromatography (HPLC) using a modified technique of Sundlof and Whitlock
(1992).The HPLC system consisted of an autosampler (WISP model 712, Waters,
Division of Millipore, Milford, MA, USA), a pump (model 590, Waters, Division of
Millipore, Milford, MA, USA), a variable wavelength ultraviolet absorption detector
(Spectroflow model 783, Applied Biosystems, Ramsey, NJ, USA), and an integrator
(model CR 501, Chromatopac, Shimadzu Scientific Instruments, Inc., Columbia, MD,
USA).
A sample of plasma (500 1.tL) was added to each test tube containing the internal
standard, ethyl paraben, and was mixed with 1 mL of ethyl acetate for 1 minute using a
vortex mixer and centrifuged at 10,000 x g for 10 minutes. The upper phase was
transferred to a clean glass test tube and evaporated at 40°C under vacuum until complete
dryness. A second extraction was performed by adding the same amount of ethyl acetate
to the remaining phase and the extraction was performed in the manner similar to that
previously described. The ethyl acetate layer obtained from the second extraction was
added to the tube containing the dried first extract and the contents were evaporated to99
dryness once again. To the resultant dry residue was added 1.5 mL of n-hexane and 2 mL
of acetonitrile; this was shaken vigorously for 1 minute, and centrifuged at 10,000 x g for
10 minutes. Thereafter the upper (hexane) layer was discarded. A second extraction was
performed using n-hexane and the hexane layer again discarded. The acetonitrile layer was
dried under vacuum at 40°C. The dry residue was reconstituted with 0.5 mL of mobile
phase containing 75% of 0.01 M potassium phosphate (pH 7.0) and 25% of acetonitrile.
Samples (100 tL) of the solutions were injected onto aC18column (Phenomenex,
Torrance, CA, USA) and scanned by an ultraviolet detector whose wavelength was set at
265 nm.
Calibration curves for the quantification of clorsulon in alpaca plasma were
obtained by plotting the ratio of peak areas of clorsulon and ethyl paraben against the
concentrations of clorsulon prepared as standard solutions. The calibration curves were
determined by linear regression analysis to be linear. Correlation coefficients of
calibration curves were greater than 0.999. The concentrations of clorsulon in the llama
plasma samples were calculated from the calibration curve using inverse prediction.
The overall percent coefficient of variation (%CV) of the clorsulon assay was 3.55
%. The % CV of clorsulon concentration in prepared standard solutions are shown in
Table 6.3. The limit of quantification was 0.029 ig/mL.100
Table 6.3 The percent coefficient of variation (%CV) of clorsulon concentration in
prepared standard solutions.
Actual conc.
(j.tg/mL)
Average of predicted
cone. Qig/mL)
SD %theoretical
cone.
%CV
0.036 0.039 0.005 108.3 12,8
0.072 0.073 0.006 101.4 8.22
0.181 0.178 0.008 98.34 4.49
0.272 0.275 0.010 101.1 3.64
0.362 0.351 0.006 96.96 1.71
0.544 0.550 0.027 101.1 4.91
1.088 1.110 0.007 102.0 0.63
Grand mean of% theoretical cone. = 101.3
Grand SD of mean % theoretical cone. = 3.60
Overall %CV = 3.55
Pharmacokinetic analysis:
The plasma concentration-time curves of clorsulon for each individual llama were
fitted by both compartmental and noncompartmental approaches with WinNonlin
Professional Version 3.2 software (Pharsight Corporation, Mountain View, California,
USA) using a weighting factor of 1/plasma concentration. The optimum number of first-
order rate processes in the predictive equation was selected on the basis of the minimal
Akaike's information criterion (Wagner, 1993 and Yamaokaetal., 1978). A linear one-
compartment open model best described clorsulon plasma concentration-time profiles after
oral administration.
For compartmental analysis, the pharmacokinetic parameters were calculated from
the equation best describing the plasma concentration-time profiles. The area under the
curve (AUC0) was calculated from the following equation.
(1)
KeKa101
F*D*Ka
where A = ,Ka = first-order absorption rate constant, Ke = first-order
V(KaKe)
elimination rate constant, V = apparent volume of distribution, and F = bioavailability.
The total body clearance (CLT) was calculated according to the following equation.
CL
Dose
(2)
AUC0
MRT is the mean residence time and is equal to
MRTAUMCQ
AUC0
(3)
where AUMC0is the area under first momentum curve, and was calculated from
AUMC0= (4)
Ke2Ka2
The apparent volume of distribution at steady state (Vss) was calculated according to
VSS=CLTXMRT (5)
Absorption half-lives were calculated from
0.693
tl/2Ka = (6)
Ka
Elimination half-lives were calculated according to
0.693
tl/2Ke = (7)
Ke
tmax was calculated from
ln(Ka IKe) tmax= (8)
i.0ie
For noncompartmental analysis,tnlaxandCrnaxwere determined from the observed
data. The MRT and terminal half-lives were calculated as stated above. The area under
the curve (AUC0) and the area under the first moment curve (AUMC0) were calculated
by the trapezoidal rule up to the last sampling time point (AUC0) and extrapolated to
infinity (AUCtCC)using the equation
AUC= (9)102
AUMC.=t*Ct
(10)
Az,2
Therefore, A UC0, = A UC( + A UC_ (11)
t*CtCt
and AUMCØ. = AUMCO + + (12)
Az Az2
The terminal volume of distribution (Vz) was calculated by the following equation.
Vz =
Az
(13)
Since the pharmacokinetics of clorsulon following intravenous administration was
not investigated in this study, some of the parameters will be reported along with F
(fraction of dose absorbed). 1fF is known, the actual value of those parameters can be
determined.
RESULTS
The plasma concentration-time curves of clorsulon following oral administration
for each llama were individually fitted using WinNonlin Professional Version 3.2 software
(Pharsight Corporation, Mountain View, California, USA). Table 6.4 shows the plasma
concentrations of clorsulon in each llama after oral administration at a single dose of 14
mg/kg body weight. Also listed in Table 6.4 are the average clorsulon concentrations with
their standard deviations at each time point. The semilogarithmic plot for each individual
llama's plasma concentrations of clorsulon after oral administration are presented in Figure
6.2, while the mean plasma concentration of clorsulon for five llamas following oral
administration along with standard deviation is depicted in Figure 6.3.
The plasma concentration-time profile after oral administration showed an
absorption phase followed by declining clorsulon plasma concentrations that followed a
mono-exponential manner, as demonstrated in Figure 6.4, according to the equation
F * D * Ka [e_A'e*te_*t} (14) Cp=
V(KaKe)103
where Cp is the plasma concentration of clorsulon at time t, D = given dose, V = volume of
central compartment, Ka = first-order absorption rate constant, Ke = first-order elimination
rate constant, and F = bioavailability.
Pharmacokinetic parameters of clorsulon after oral administration obtained from
compartmental and noncompartmental analysis are summarized in Tables6.5and6.6,
respectively.Table 6.4 Plasma concentrations of clorsulon (tg/mL) in five llamas at each sampling timepoint after 14 mg/kg single dose oral
administration.
Time Clorsulon plasma concentrations (jiglmL)
(h) Llama 1 Llama 2 Llama 3 Llama 4 Llama 5 Average SD
0.5 0.0594 0.1027 0.1220 0.0877 0.0526 0.0849 0.0291
1 0.0971 0.2342 0.2086 0.2527 0.1221 0.1829 0.0693
2 0.2334 0.2854 0.2252 0.2727 0.2256 0.2485 0.0285
3 0.2720 0.3011 0.3797 0.3294 0.2869 0.3138 0.0425
4 0.3314 0.3236 0.4115 0.3940 0.3381 0.3597 0.0401
6 0.3851 0.3782 0.6072 0.5634 0.3762 0.4620 0.1137
8 0.4645 0.4104 0.6611 0.6431 0.4770 0.5312 0.1133
12 0.7092 0.4366 0.8106 0.6923 0.5984 0.6494 0.1408
24 0.7891 0.5177 0.8537 0.7128 0.6553 0.7057 0.1292
36 0.6547 0.4792 0.7748 0.6431 0.6091 0.6322 0.1060
48 0.5519 0.3811 0.6431 0.5334 0.4818 0.5182 0.0963
72 0.3607 0.2504 0.3621 0.3592 0.3381 0.3341 0.0478-J
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Figure 6.2 Semilogarithmic plot of individual clorsulon plasma concentration-time curve in
llamas after a 14 mg/kg single dose oral administration.
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Figure 6.3 Semilogarithmic plot of average plasma concentration-time curve of clorsulon
in llamas after oral administration at a single dose of 14 mg/kg.Table 6.5 Pharmacokinetic parameters of clorsulon after oral administration(14 mg/kg) using compartmental analysis.
Parameters Llama 1 Llama 2 Llama 3 Llama 4 Llama 5 Average SD
Ka(h1) 0.087 0.419 0.113 0.174 0.125 0.184 0.135
Ke(h) 0.020 0.006 0.019 0.013 0.014 0.015 0.005
T(h) 22.1 10.2 18.9 16.0 19.5 17.3 4.55
C(jtg/mL) 0.748 0.445 0.890 0.735 0.652 0.694 0.163
tl/2,Ka(h) 7.98 1.66 6.11 3.98 5.53 377* 2.38
tI!2 (I(h) 35.2 110.6 36.1 52.2 48.3 47.6* 31.2
MRT(h) 50.5 159.2 51.9 75.6 69.8 81.4 44.8
AUC
(tg.hImL)
58.7 75.6 66.6 68.5 60.1 65.9 6.83
CLT/F
(mL/kg/h)
0.239 0.185 0.210 0.204 0.233 0.214 0.022
Vc/F
(mt/kg)
12.1 29.5 11.0 15.4 16.2 16.8 7.43
= harmonic meanTable 6.6 Pharmacokinetic parameters of clorsulon after oral administration(14 mg/kg) using noncompartmental analysis.
Parameters Llama 1 Llama 2 Llama 3 Llama 4 Llama 5 Average SD
C11(ig/mL) 0.789 0.518 0.854 0.713 0.655 0.706 0.129
(h) 24 24 24 24 24 24 0
0.017 0.018 0.022 0.016 0.016 0.018 0.002
t112(h) 41.4 38.6 32.2 42.7 43.0 39.1* 449
MRT (h) 68.5 64.8 56.4 69.4 71.4 66.1 5.92
AUCOOO
(j.tg'hImL)
61.9 42.5 63.1 62.2 56.9 57.3 8.65
CLZ/F
(mL/kg/h)
0.226 0.330 0.222 0.225 0.246 0.250 0.046
Vss/F
(nit/kg)
15.5 21.4 12.5 15.6
-
17.6 16.5 3.26
Vz/F
(mL/kg)
13.5 18.4 10.3 13.9 15.3 14.3 2.92
= harmonic meanDISCUSSIONS AND CONCLUSION
The pharmacokinetic behavior of clorsulon in llamas after oral administration of a
single dose of 14 mg/kg of body weight was best described by a one-compartment open
model on the basis of minimal AIC when fitting the data. This conclusion is in agreement
with the results of previous studies earned out on sheep and goats (Sundlof and Whitlock,
1992). The harmonic mean elimination half-life in llama was 39.15 h whereas 27.86 h and
22.40 h were reported in sheep and goats, respectively (Sundlof and Whitlock, 1992).
Schulman et al. (1982) reported an elimination half-life of 12.79 h and 10.68 h in old and
young rats, respectively. Time to reach maximum concentration in the blood (tniax) for
llamas was 24 h compared to 15.18 ± 5.12 h, 13.92 ± 7.32 h, 2-4 h in sheep (Sundlof and
Whitlock, 1992), goats (Sundlof and Whitlock, 1992), and rats (Schulman et al., 1982),
respectively. Plumb (1995) reported tnlax of 4 h in cattle after oral administration of
clorsulon at a single dose of 7 mg/kg of body weight. The harmonic mean absorption half-
life of clorsulon in llamas was 3.77 h and the maximum clorsulon concentration was 0.71 ±
0.13 jig/mL after being given a single oral dose of 14mg/kg.
Although the pharmacokinetics of clorsulon following intravenous administration
was not investigated in this study, Sundlof and Whitlock (1992) reported that a three-
compartment open model best described the plasma concentration-time profiles of
clorsulon in both sheep and goats after a single intravenous dose of 7 mg/kg of body
weight. In goats, a single oral dose of clorsulon of 7 mg/kg was 98% effective against
mature flukes (Sundlofet al., 1991) while the efficacy of 90-100% was reported when the
same dose of clorsulon was orally given to sheep infected with mature flukes (Ostlind et
al., 1977; Fairweather and Boray, 1999). The maximum clorsulon plasma concentration
(Cmax) produced by a single oral dose of 7 mg/kg in goats and sheep were 1.19 ± 0.50 and
1.60 ± 0.47 1g/mL, respectively (Sundlof and Whitlock, 1992). These plasma values of
clorsulon in goats and sheep after 7 mg/kg oral dose are higher than 0.71 ± 0.12 j.tg/mL
plasma levels observed in llamas in this study after a 14 mg/kg oral dose. This suggests
not the entire oral dose is absorbed in llamas.109
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CHAPTER 7
EVALUATION OF THE AREA UNDER THE CURVE EQUATIONS FOR
PHARMACOKINETIC SYSTEMS WITH NONLINEAR ELIMINATION
Triporn Wattananat and J. Mark Christensen114
ABSTRACT
Since the differential equations describing one-compartment system with first-
order input and two-compartment system after IV administration with nonlinear
elimination kinetics cannot be solved, there is no mathematical expression for plasma
concentration-time curves and consequently no simple expression for the area under the
curve (AUC) for drugs following these models. Preliminary AUC equations were designed
for drugs following these models and these equations predictions for AUC were calculated
and were compared to AUC that were calculated using the trapezoidal rule method based
on computer-generated data. The computer generated data for the concentration-time
curves for the two nonlinear models were generated from the differential equations and
numerically integrated using the fourth-order Runge-Kutta method. Except for a few
exceptions the predicted AUC's from the proposed AUC equations matched the AUC's
that were calculated from the theoretically generated numerically integrated data.115
INTRODUCTION
The area under the plasma level versus time curve (AUC) is a measurement of the
amount of drug absorbed to the systemic circulation. In linear pharmacokinetics, the AUC
is linearly proportional to the dose administered for drugs eliminated by first-order
kinetics. However, for drugs that are eliminated by capacity-limited processes or
Michaelis-Menten kinetics, the AUC is not linearly proportional to the administered dose.
The AUC increases overproportionally with increasing dose due to saturation of the
clearance mechanism.
Michaelis-Menten kinetics can be described by the equation:
dCVm*C
(1
dtKin+C
wheredC/dt is the rate of decline in drug concentration at time t, C is the drug
concentration, Vm is the maximum rate of metabolism, and Km is Michaelis-Menten
constant.
When the drug concentration is considerably greater than Km, C >> Km, equation
(1) reduces to
dC
- - = Vni
di'
(2)
Under this condition, the elimination rate of the drug is independent of drug concentration,
thus the drug elimination becomes a zero-order process.
When the drug concentration is much lower than Km, C <<Km, equation (1)
reduces to
(3)
di' Kin
Under this condition, the drug elimination becomes a first-order process.
At intermediate concentrations, the plasma concentration decline at a variable rate
as a function of the varying plasma concentrations as described in equation (1). Currently,
only the mathematical expression for describing the AUC for drugs following nonlinear
pharmacokinetics or drugs obeying a one-compartment open model with single Michaelis-
Menten elimination kinetics after intravenous (IV) administration is available. There are116
no simple expressions for AUC for drugs following one-compartment model with first-
order absorption or two-compartment model after IV administration eliminated from the
central compartment in a nonlinear fashion.
Equations to predict AUC for drugs following one-compartment open model with
first-order absorption and Michaelis-Menten elimination kinetics and a two-compartment
open model with IV administration and Michaelis-Menten elimination kinetics have been
proposed. How well these equations work and the boundary of their accuracy is unknown.
The objective of this study is to compare the AUC predicted by these equations for
drugs following pharmacokinetic systems with nonlinear elimination to AUCs obtained
using the trapezoidal rule method from data numerically generated plasma concentration-
time curves using the differential equations by computer simulation and to test the limits of
accuracy these proposed equations for AUC have.
THEORETICAL
One Compartment Model
IJ"-bolus administration
The model for a drug which follows one-compartment system having only
Michaelis-Menten elimination kinetics after single intravenous dose can be illustrated as
shown in Figure 7.1.
Km
D V
at t = 0
Vm
Figure 7.1 Schematic diagram of a drug following one-compartment open model with
Michaelis-Menten elimination kinetics after intravenous bolus administration.The rate of decline of drug concentration (C) with time (t) can be described by the
following equation.
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dC V,n*C
(4)
dt K,n+C
where V = the apparent volume of distribution (unitsvolume)
Vm = the maximum elimination rate (units = amount/time)
Km = the plasma concentration at which the rate of metabolism is one-half of its
maximum (units = concentration)
Rearrangement of equation (4) yields equation (5).
-Vrn'*C
dt Kin + C
where Vm' = Vm/V
(5)
Inversion and rearrangement of equation (5) gives equation (6).
Cd=-'dC---dC (6)
Vin' Viii'
Since at t = 0, C(t) =C0and at t = ,C(t) = 0, integration of equation (6) from time zero to
infinity yields equation (7).
$ Cdt= A UC0
Kin C0
Vin' 2V,n'
0
AUCQ=c-JK,n+22l
2 ]
D r Dl AUC0= IKrn+I
V*V,n'L 2Vj
DrD 1
AUCQ +K,nI (7)
vniL2v ]
First-Order Absorption
The model for a drug that follows one-compartment system with only Michaelis-
Menten elimination kinetics after single first-order input can be depicted as seen in Figure
7.2.at t = 0
Ka I I Km
Vm
Figure 7.2 Schematic diagram of a drug following one-compartment open model with
Michaelis-Menten elimination kinetics and first-order absorption.
The differential equation for the model in Figure 7.2 is given as equation (8).
dC V,n*C V * - = KaFDe*( (8)
dt K,n+C
Rearrangement of equation (8) yields equation (9).
dCKaFDe*tVm*C
(9)
dt V Krn+C
where Vm' = VmIV
Ka = the apparent first-order absorption rate constant (units =time1)
F = fraction of dose absorbed
Since both equation (8) and its arrangement, equation (9), cannot be integrated,
there is no mathematical expression or AUC equation of drugs following this model. Al-
Ghazawi (1998) proposed a preliminary equation for the calculation of AUC for drugs
obeying one-compartment open model eliminated in nonlinear fashion as shown in
equation (10).
KaFD [Km+C0/2ii
AUC0_ = (10)
Vin' Vm' Ka]
VIKa
Km+C0)119
Two-Compartment Model
IV bolus administration
The model for a drug which follows one-compartment system having only
Michaelis-Menten elimination kinetics from the central compartment after single
intravenous dose can be illustrated as shown in Figure 7.3.
Iv
Dose
Figure 7.3 Schematic diagram of a drug following two-compartment system with
Michaelis-Menten elimination kinetics from the central compartment after IV bolus
administration.
The rate of decline of drug concentration (C) with time (t) can be described by the
following equations.
dCV,n*CDCC (11) V -= CL C
dtKm+C R
T
R dt R
(12)
where V( = the apparent volume of distribution of the central compartment
V1= the apparent volume of distribution of the tissue compartment
CLD= the intercompartmental or distribution clearance (units = volume/time)
C = drug concentration in the central compartment120
Cr = drug concentration in the tissue compartment
R = the tissue: plasma distribution ratio
It is assumed that an intravenous bolus dose of drug into the central compartment produces
initial conditions ofC0= D/V andCT(0) = 0.
Based on the computer simulations, Cheng and Jusko (1989) found that equation
(13) from which V in equation (7) is substituted by Vss has been shown to be a
meaningful AUC equation of drugs following two-compartment system with IV
administration and Michaelis-Menten elimination kinetics from the central compartment.
(13)
VmL2Vss j
METHODS
Plasma concentration-time profiles after intravenous and oral administrations were
generated by numerical integration of the differential equations (5), (9), (11), and (12)
using WinNonlin Professional Version 3.2 software (Pharsight Corporation, Mountain
View, California, USA).
For one-compartment system, simulations were performed by using the following
values: Dose = 50, 100, 500, 1000, 2500, and 5000 mg, Vm = 5, 10, 20, and 40 mg/hr. Km
= 1,4, 10, and 20 mg/L, Ka=0.3, 0.75,1,2, and4hr1, V =44.8 L, andF= 1.
For two-compartment system, simulated data were carried out with dose = 50, 100,
500, 1000, 2500, and 5000 mg, Vm = 5, 10, 20, 40, and 50 mg/hr, Km = 1, 4, 10, and 20
mg/L, V = 25.6 L,VT= 19.2 L,CLD= 28.7 L/hr, and R = 1.
The areas under the plasma concentration-time curves were calculated by
trapezoidal rule method and compared with those directly obtained from equations (7),
(10), and (13).
Six doses were used in the simulations of the one- and two-compartment open
model cases to assure that the pseudo-first-order, Michaelis-Menten, and initial pseudo-
zero-order elimination behavior would be observed in the limiting low-dose, middle, and121
high-dose cases. In addition, five different values of Ka were used to illustrate the effect of
the absorption rate constant on the AUC.
To show how well equations (7), (10), and (13) can predict AUC in the different
situations, the simulations of all combinations of dose, Vm, Km, and Ka were performed
for both one- and two-compartment systems. The actual differences and the percentage of
the differences in AUC estimation between equations (7), (10), (13) and the trapezoidal
rule method were calculated using the AUC obtained from the trapezoidal rule method as
the reference.
RESIJLTS
One-Compartment Model
IV bolus administration
The simulated plasma concentration-time data for all combinations of dose, Vm,
and Km were generated using equation (5). Figure 7.4 shows the simulated plasma
concentration-time profiles of six doses when Vm = 20 mg/hr and Km = 4 mg/L. The
companson of area under the simulated plasma concentration-time curves calculated
directly from equation (7) and trapezoidal rule method along with the percentage of the
differences in AUC estimation between these two methods are shown in Table 7.1.
The curves exhibit first-order behavior at the low dose and pseudo zero-order
behavior at the early time of the medium and high dose when the drug plasma
concentration is greater than Km. The percent difference in predicted AUCs from equation
(7) and the numerically integrated AUCs using the trapezoidal rule range from 0.000049 %
to 0.000736 %, showing the accuracy of equation (7) and the accuracy of the method to
study the equations.122
First-order absorption
The simulated plasma concentration-time data for all combinations of dose, Vm,
Km, and Ka were generated using equation (9). Figures 7.5 and 7.6 show the simulated
plasma concentration-time profiles when Vm = 20 mg/hr and Km = 4 mg/L, and Ka =
br at different doses while Figure 7.7 shows a plot of the simulated plasma concentration-
time curves at different values of the absorption rate constant when dose = 500 mg, Vm =
20 mg/hr. and Km =4 mg/L.
The comparison of area under the simulated plasma concentration-time curves
calculated directly from equation (10) and trapezoidal rule method along with the
percentage of the differences in AUC estimation between these two methods at the doses
of 50, 100, 500, 1000, 2500, and 5000 mg are shown in Table 7.2, 7.3, 7.4, 7.5, 7.6, and7.7,
respectively.
Based on the results shown in Tables 7.2 to 7.7, equation (10) yielded good
approximation of the AUC except under the conditions of two cases; clearance ratio
(VmIKm) greater than 4 with Ka in the range of 0.3-0.75, and clearance ratio (VmiKm)
greater than 10 with Ka in the range of 1-2. Equation (10) gave good approximation when
Ka is very fast with most of the values of dose, Vm, and Km used in this study. With the
same value of Ka, the % difference in AUC estimation using equation (10) tends to be
higher with decreasing dose, as seen in Figures 7.8, 7.9, and 7.10. Figure 7.11
demonstrates the effect of Ka on AUC with the same conditions of dose, Vm, and Km.
Two-Compartment Model
I V-bolus administration
The simulated plasma concentration-time data for all combinations of dose, Vm,
and Km were generated using equations (11) and (12). Figure 7.12 shows the simulated
plasma concentration-time profiles of six doses when Vm = 20 mg/hr, Km = 4 mg/L,CLD
= 28.7 L/hr, V = 25.6 L,VT= 19.2 L, and R = 1. The comparison of area under the
simulated plasma concentration-time curves calculated directly from equation (13) and the
trapezoidal rule method along with the percentage of the differences in AUC estimation123
between these two methods are shown in Table 7.8.
Based on the results shown in Table 7.8, equation (13) overall yielded better
approximation for AUC than equation (10). However under the conditions of low dose
(50 and 100 mg) with clearance ratio (VmIKm) greater than 10, the % difference in AUC
estimation larger than acceptable errors were observed.
1000
100
10
-I
)
E
C
.2 0.1
I-
C
8 0.01
C
0
C.)
0.001
0.0001
0.00001
0 1 2 3 4 5 6 7 8 9 10
Time (hr)
Figure 7.4 Simulated plasma concentration-time profiles for the one-compartment
system following IV bolus administration using equation (2) at various doses when Vm
20 mg/br, Km = 4 mg/L, and V = 44.8 L.Table 7.1 Comparison of AUC at different doses and clearance ratios (VmIKm) of drug forone-compartment Michaelis-Menten
system after IV bolus administration.
Dose
(mg)
Vm
(mg/hr)
Km
(mgIL)
VmIKm
(L/hr)
AUC (equation 7)
(mghr/L)
AUC (trapezoidal)
(mg'hr/L)
%difference in AUC
estimation
50 5 1 5 15.580357 15.580424 0.000427
4 1.25 45.580357 45.580471 0.000250
10 0.5 105.58036 105.58043 0.000068
20 0.25 205.58036 205.58170 0.000653
50 10 1 10 7.7901786 7.7902294 0.000653
4 2.5 22.790179 22.790272 0.000408
10 1 52.790179 52.790284 0.000201
20 0.5 102.79018 102.79031 0.000129
50 20 1 20 3.8950893 3.8951266 0.000478
4 5 11.395089 11.395144 0.000361
10 2 26.395089 26.395185 0.000257
20 1 51.395089
-
51.395221 0.000372
50 40 1 40 1.9475446 1.9475519 0.000372
4 10 5.6975446 5.6975855 0.000719
10 4 13.197545 13.197607 0.000472
20 2 25.697545 25.697644 0.000388
N)Table 7.1 (Continued)
Dose
(mg)
Vm
(mg/br)
Km
(mg/L)
Vm!Km
(L/br)
AUC (equation 7)
(mghr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
50 50 1 50 1.558036 1.55804 0.000387
4 12.5 4.558035 4.55807 0.000314
10 5 10.55804 10.5581 0.000587
20 2.5 20.55804 20.5812 0.000417
100 5 1 5 42.32143 42.3216 0.000447
4 1.25 102.3214 102.322 0.000238
10 0.5 222.3214 222.321 0.000135
20 0.25 422.3214 422.324 0.000693
100 10 1 10 21.16071
-
21.1608 0.000482
4 2.5 51.16071 51.1609 0.000412
10 1 111.1607 111.161 0.000205
20 0.5 211.1607 211.161 0.000131
100 20 1 20 10.58036 10.5804 0.000476
4 5 25.58036
-
25.5805 0.000487
10 2 55.58036 55.5806 0.000380
20 1 105.5804
-
105.581 0.000209Table 7.1 (Continued)
Dose
(mg)
Vm
(mg/hr)
Km
(mg/L)
Vm/Km
(L/hr)
AUC (equation 7)
(mghr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
100 40 1 40 5.29017 5.29020 0.000558
4 10 12.7901 12.7902 0.000735
10 4 27.7901
-
27.7903 0.000494
20 2 52.7901 52.7903 0.000381
100 50 1 50 4.23214 4.23215 0.000296
4 12.5 10.2321 10.2322 0.000860
10 5 22.2321 22.2322 0.000529
20 2.5 42.232 1 42.2323 0.000430
1000 5 1 5 2432.14
-
2432.14 0.000061
4 1.25 3032.14
- -
3032.14 0.000049
10 0.5 4232.14 4232.15 0.000117
20 0.25 6232.14 6232.17 0.000415
1000 10 1 10 1216.07 1216.07 0.000181
4 2.5 1516.07 1516.07 0.000123
10 1 2116.07--
2116.07 0.000079
20 0.5 3116.07 3116.07 0.000090Table 7.1 (Continued)
Dose
(mg)
Vm
(mg/hr)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 7)
-
(mg.hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
1000 20 1 20 608.0357 608.0393 0.000603
4 5 25.58035 25.58048 0.000402
10 2 1058.035 1058.038 0.000231
20 1 1558.035 1558.037 0.000128
1000 40 1 40 304.0178 304.0194 0.000509
4 10 379.0178 379.0194 0.000425
10 4 529.0178
-
529.0202 0.000459
20 2 779.0178 779.0203 0.000324
1000 50 1 50 243.2142 243.2150 0.000297
4 12.5 10.23214 10.23223 0.000447
10 5 423.2142
--
423.2162 0.000459
20 2.5 623.2142 623.2167 0.0003932.5
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Figure 7.5 Simulated plasma concentration-time profiles for the one-compartment system
with first-order absorption using equation (6) when Vm = 20 mg/hr, Km = 4 mg/L, V =
44.8 L, and Dose = 50, 100, and 500 mg.
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Figure 7.6 Simulated plasma concentration-time profiles for the one-compartment system
with first-order absorption using equation (6) when Vm = 20 mg/br, Km = 4 mg/L, V =
44.8 L, and Dose = 1000, 2500, and 5000 mg.-I
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Figure 7.7 Simulated plasma concentration-time profiles for the one-compartment system
with first-order absorption using equation (6) when dose = 500 mg, Vm = 20 mglhr, Km =
4 mg/L, V = 44.8 L, and Ka = 0.3, 0.5, 0.75, 1, 2, and 4 hr'.Table 7.2 Comparison of AUC at different Ka and clearance ratios (VmlKm) of drug forone-compartment Michaelis-Menten system
with first-order input at the dose of 50mg.
Dose
(mg)
Ka
(br')
Vm
(mg/hr)
Km
(mg/L)
Vm!Km
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
50 0.3 5 1 5 14.390007 14.491003 -0.696950
4 1.25 45.142750 45.146466 -0.008230
10 0.5 105.38713 105.37960 0.0071416
20 0.25 205.48027 205.45166 0.0139287
50 0.3 10 1 10 6.2770665 6.8345047 -8.156234
4 2.5 22.315335 22.398016 -0.369143
10 1 52.590022 52.600571 -0.020055
20 0.5 102.68827 102.67691 0.01 10642
50 0.3 20 1 20 0.5891905 3.1515973 -81.30501
4 5 10.822862 11.047148 -2.030258
10 2 26.179464 26.219708 -0.153484
20 1 51.289320 51.293909 -0.008945
50 0.3 40 1 40 4.3611939 1.4493550 200.90583
4 10 4.7273851 5.4150593 -12.69929
10 4 12.942500 13.041965 -0.762649
20 2 25.583099 25.605850 -0.088849Table 7.2 (Continued)
Dose
(mg)
Ka
(hf')
Vm
(mg/hr)
Km
(mg/L)
Vm!Km
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg.br/L)
%difference in AUC
estimation
50 0.75 5 1 5 15.158242 15.105711 0.347757
4 1.25 45.413180 45.391004 0.048856
10 0.5 105.50463 105.46293 0.039544
20 0.25 205.54075 205.46546 0.036650
50 0.75 10 1 10 7.3335208 7.3410860 -0.103052
4 2.5 22.617838 22.614067 0.0166795
10 1 52.713419 52.694208 0.0364583
20 0.5 102.75029 102.71169 0.0375808
50 0.75 20 1 20 3.3490660 3.4911543 -4.069950
4 5 11.211404 11.231444 -0.178434
10 2 26.316159 26.311675 0.0170417
20 1 51.354622 51.336593 0.0351185
50 0.75 40 1 40 1.0503811 1.6194981 -35.141567
4 10 5.4860072 5.5504728 -1.1614446
10 4 13.113881 13.122479 -0.0655206
20 2 25.655869 25.650264 0.02184924Table 7.2 (Continued)
Dose
(mg)
Ka
(br')
Vm
(mg/hr)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mgbr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
50 1 5 1 5 15.269646 15.216042 0.3522912
5 4 1.25 45.455906 45.427111 0.0633888
5 10 0.5 105.52376 105.47035 0.0506355
5 20 0.25 205.55070 205.44978 0.0491227
50 1 10 1 10 7.461 1480 7.4430279 0.2434507
10 4 2.5 22.662889 22.651328 0.0510380
10 10 1 52.733002 52.707149 0.0490509
10 20 0.5 102.76036 102.71068 0.0483717
50 1 20 1 20 3.5220707 3.5750466 -1.4818248
20 4 5 11.261715 11.266816 -0.0452746
20 10 2 26.336717 26.326179 0.04002516
20 20 1 51.364957 51.340864 0.04692834
50 1 40 1 40 1.4383879 1.6822253 -14.494928
40 4 10 5.5500722 5.6035732 -0.9547662
40 10 4 13.136623 13.190102 -0.4054460
40 20 2 25.666747 25.759464 -0.3599334
-ITable 7.2 (Continued)
Dose
(mg)
Ka
(hr)
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/br)
AUC (equation 10)
(mghr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
50 2 5 1 5 15.429209 15.380308 0.3179505
5 4 1.25 45.518818 45.466809 0.1143888
5 10 0.5 105.55220 105.44629 0.1004401
5 20 0.25 205.56557 205.36541 0.0974638
50 2 10 1 10 7.6348234 7.6031493 0.4165920
10 4 2.5 22.727953 22.701439 0.1167948
10 10 1 52.761880 52.708894 0.1005268
10 20 0.5 102.77535 102.67532 0.0974255
50 2 20 1 20 3.7305740 3.7191553 0.3070228
20 4 5 11.331444
-
11.319646 0.1042292
20 10 2 26.366501 26.340378 0.0991726
20 20 1 51.380184 51.330304 0.0971752
50 2 40 1 40 1.7610353 -
1.7864068 -1.420250
40 4 10 5.6308777 5.6304428 0.0073690
40 10 4 13.168358 13.156510 0.0900542
40 20 2 25.682478 25.657889 0.0958345Table 7.2 (Continued)
Dose
(mg)
Ka
(hr')
Vm
(mg/br)
Km
(mg/L)
Vm/Km
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
50 4 5 1 5 15.505793 15.449671 0.3632583
5 4 1.25 45.549756 45.450784 0.2177562
5 10 0.5 105.56631 105.35090 0.2044682
5 20 0.25 205.57297 205.17279 0.1950424
50 4 10 1 10 7.7146049 7.6802831 0.4468820
10 4 2.5 22.759409 22.709215 0.2210273
10 10 1 52.776100 52.670504 0.2004857
10 20 0.5 102.78278 102.58266 0.1950853
50 4 20 1 20 3.8174117 3.7967082 0.5453008
20 4 5 11.363976 11.338662 0.2232567
20 10 2 26.380940 26.328135 0.2005631
20 20 1 51.387676 51.287634 0.1950609
50 4 40 1 40 1.8652870 1.8572018 0.4353414
40 4 10 5.6657223 5.6538282 0.2103725
40 10 4 13.183250 13.157048 0.1991513
40 20 2 25.690092 25.640134 0.1948430Table 7.3 Comparison of AUC at different Ka and clearance ratios (VmIKm) of drug forone-compartment Michaelis-Menten system
with first-order input at the dose of 100 mg.
Dose
(mg)
Ka
(br')
Vm
(mg/br)
Km
(mg/L)
Vm/Km
(L/hr)
AUC (equation 10)
(mghr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
100 0.3 5 1 5 39.418016 38.984149 1.1129329
5 4 1.25 100.90437 100.84336 0.0604949
5 10 0.5 221.62125 221.58169 0.0178537
5 20 0.25 421.94155 421.87793 0.0150810
100 0.3 10 1 10 17.823180 18.059814 -1.3102817
10 4 2.5 49.647602 49.756289 -0.2184399
10 10 1 110.43787 110.44682 -0.0081070
10 20 0.5 210.77426 210.75954 0.0069842
100 0.3 20 1 20 5.8189602 7.9627924 -26.923119
20 4 5 23.829931 24.304123 -1.9510747
20 10 2 54.807454 54.919322 -0.2036950
20 20 1 105.18004 105.20102 -0.0199413
100 0.3 40 1 40 -27.15375 3.4062052 -897.18501
40 4 10 10.239741 11.722392 -12.648027
40 10 4 26.893015 27.195046 -1.1106132
40 20 2 52.358929 52.43940 -0.1534536Table 7.3 (Continued)
Dose
(mg)
Ka
(hr')
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
100 0.75 5 1 5 41.244139 40.091786 0.7973878
5 4 1.25 101.77540 101.67726 0.0965229
5 10 0.5 222.04653 221.94829 0.0442638
5 20 0.25 422.17101 422.01006 0.0381378
100 0.75 10 1 10 20.028796 19.801321 1.1487850
10 4 2.5 50.600999 50.549325 0.1022246
10 10 1 110.88239 110.83389 0.0437606
10 20 0.5 211.00927 210.92572 0.0396150
100 0.75 20 1 20 9.3206828 9.2983107 0.2406041
20 4 5 24.991090 25.001205 -0.040460
20 10 2 55.294916 55.281106 0.0249827
20 20 1 105.42683 105.39023 0.0347343
100 0.75 40 1 40 3.6632522 4.1664105 -12.07654
40 4 10 12.131340 12.257053 -1.025638
40 10 4 27.489350 27.513311 -0.086390
40 20 2 52.632318 52.623333 0.0170737
C'Table 7.3 (Continued)
Dose
(mg)
Ka
(hf')
Vm
(mg/hr)
Km
(mgIL)
Vm/Km
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg.hrIL)
%difference in AUC
estimation
100 1 5 1 5 41.249684 41.523094 0.662816
5 4 1.25 101.81056 101.91440 0.101991
5 10 0.5 221.99040 222.11589 0.056526
5 20 0.25 421.99578 422.20880 0.050480
100 1 10 1 10 20.122206 20.332768 1.046414
10 4 2.5 50.685344 50.746126 0.119196
10 10 1 110.88694 110.95326 0.059805
10 20 0.5 210.94566 211.04752 0.048286
100 1 20 1 20 9 5880777 9 6860691 1 022013
20 4 5 25.131749 25.149774 0.071721
20 10 2 55.341100 55.368979 0.050377
20 20 1 105.41406 105.46600 0.049276
100 1 40 1 40 4.3872401 4.2252249 -3.692872
40 4 10 12.323593 12.372280 -0.393516
40 10 4 27.570479 27.571921 -0.005230
40 20 2 52.673434 52.652220 0.0402916Table 7.3 (Continued)
Dose
(mg)
Ka
(br')
Vm
(mg/hr)
Km
(mg/L)
Vm/Km
(L/br)
AUC (equation 10)
(mghr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
100 2 5 1 5 41.929274 41.735697 0.463815
5 4 1.25 102.11975 101.97614 0.140828
5 10 0.5 222.21913 221.98183 0.106898
5 20 0.25 422.26525 421.84216 0.100297
100 2 10 1 10 20.761547 20.609917 0.735713
10 4 2.5 50.957200 50.875910 0.159781
10 10 1 111.05794 110.93726 0.108781
10 20 0.5 211.10440 210.89739 0.098157
100 2 20 1 20 10.166384 10.053821 1.119599
20 4 5 25.373063 25.328120 0.177442
20 10 2 55.476633 55.415694 0.109965
20 20 1 105.52376 105.41784 0.100472
100 2 40 1 40 4.843034 4.7905520 1.095543
40 4 10 12.574887 12.558691 0.128958
40 10 4 27.684489-
27.656178 0.102370
40 20 2 52.733002 52.68073 1 0.099222Table 7.3 (Continued)
Dose
(mg)
Ka
(hr')
Vm
(mg/br)
Km
(mgIL)
Vm/Km
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
100 4 5 1 5 42.127058 41.936041 0.455497
5 4 1.25 102.22104 101.97149 0.244725
5 10 0.5 222.27039 221.80394 0.210299
5 20 0.25 422.29337 421.44966 0.200193
100 4 10 1 10 20.964637 20.837616 0.609572
10 4 2.5 51.059876 50.929180 0.256622
10 10 1 111.10956 110.87502 0.211536
10 20 0.5 211.13263 210.71547 0.197971
100 4 20 1 20 10.380773 10.290022 0.881934
20 4 5 25.478600 25.408646 0.275313
20 10 2 55.528972 55.410766 0.213326
20 20 1 105.55220 105.34108 0.200408
100 4 40 1 40 5.0831920--
5.0325749 1.005789
40 4 10 12.686531 12.649494 0.292792
40 10 4 27.738316 27.678982 0.214364
40 20 2 52.761880 52.656241 0.200619Table 7.4 Comparison of AUC at different Ka and clearance ratios (VmIKm) of drug forone-compartment Michaelis-Menten system
with first-order input at the dose of 500mg.
Dose
(mg)
Ka
(hr')
Vm
(mg/hr)
Km
(mgIL)
VmIKm
(L/hr)
AUC (equation 10)
(mghr/L)
AUG (trapezoidal)
(mg.hr/L)
%difference in AUG
estimation
500 0.3 5 1 5 640.42539 629.16356 1.789969
5 4 1.25 943.99786 938.58940 0.576224
5 10 0.5 1548.0493 1545.6416 0.155777
5 20 0.25 255 1.2928 2550.0066 0.050442
500 0.3 10 1 10 310.83369 300.41228 3.469034
10 4 2.5 464.61767 459.88562 1.028963
10 10 1 768.84956 766.91910 0.251717
10 20 0.5 145.05704 1271.2957 0.070545
500 0.3 20 1 20 224.32510 136.87169 6.3681 18
20 4 5 378.95605 377.75210 1.563537
20 10 2 632.51249
j
632.03163 0.318716
20 20 1 59.650943 55.480792 0.076096
500 0.3 40 1 40 102.71624 102.14609 7156386
40 4 10 183.33802 183.57956
40 10 4 312.38862 312.59598 -0.131576
40 20 2 312.38862 312.59598 -0.066332
CTable 7.4 (Continued)
Dose
(mg)
Ka
(br')
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
500 0.75 5 1 5 651.12248 646.08798 0.779228
5 4 1.25 952.50403 949.76063 0.288852
5 10 0.5 1554.0836 1552.4233 0.106943
5 20 0.25 2555.3580 2553.8696 0.058280
500 0.75 10 1 10 322.01791 317.31152 1.483205
10 4 2.5 473.43079 471.04313 0.506888
10 10 1 775.03757 773.80245 0.159616
10 20 0.5 1276.3272 1275.4343 0.070008
500 075 20 1 20 15732884
-
15296610 2852099
20 4 5 233.80770 231.73324 0.895195
20 10 2 385.47104 384.52259 0.246656
20 20 1 636.79210-
636.22346 0.089376
500 075 40 1 40 74684799 70892783
40 4 10 11381032 11218353 1t1
40 10 4 190.59622 189.94643 0.342092
40 20 2 316.98368 316.64943 0.105556Table 7.4 (Continued)
Dose
(mg)
Ka
(bY')
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
500 1 5 1 5 652.86680 -
648.95374 0.602979
5 4 1.25 953.89721 951.67832 0.233154
5 10 0.5 1555.0768 1553.6194 0.093808
5 20 0.25 2556.0298 2554.6053 0.055762
500 1 10 1 10 323 80061 320 16981 1 13424
10 4 2.5 474.84843 472.95237 0.400898
10 10 1 776.04325 774.99729 0.134962
10 20 0.5 1277.0047 1276.1767 0.064877
500 1 20 1 20 159 19227
-
155 80106 2 176629
20 4 5 235.27625 233.61617 0.710600
20 10 2 386.50227 385.70285 0.207261
20 20 1 637.48118 636.96235 0.081453
500 1 40 1 40 76 727169 73 668895 4J51376
40 4 10 11538935 11400557 1213783
40 10 4 191.68158 191.09109 0:309008
40 20 2 317.69681 317.37241 0.102212
t'JTable 7.4 (Continued)
Dose
(mg)
Ka
(hr)
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mghr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
500 2 5 1 5 655.46317 -
653.27203 0.335410
5 4 1.25 955.97410 954.58021 0.146021
5 10 0.5 1556.5602 1555.4455 0.071663
5 20 0.25 2557.0345 2555.7127 0.051719
500 2 10 1 10 326.43340 324.47660 0.603061
10 4 2.5 476.94860 475.83969 0.233042
10 10 1 777.53844 776.81151 0.093578
10 20 0.5 1278.0149 1277.3144 0.054839
500 2 20 1 20 161.90030 160.08475 1.134121
20 4 5 237.42412 236.47619 0.400893
20 10 2 388.02162 387.49880 0.134920
20 20 1 638.50237 638.08946 0.064709
500 2 40 1 40 79596138 77900756 2iZ6335
40 4 10 117.63812 116.80825 0.710458
40 10 4 193.25113
-
192.85141 0.207266
40 20 2 318.74059 318.48117 0.081453Table 7.4 (Continued)
Dose
(mg)
Ka
(lift)
Vm
(mg/hr)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg'hr/L)
%difference in AUC
estimation
500 4 5 1 5 656.75240 655.44633 0.199263
5 4 1.25 957.00681 956.04816 0.100271
5 10 0.5 1557.2989 1556.3771 0.059228
5 20 0.25 327.73158-
2556.3494 0.046400
500 4 10 1 10 477.98705 326.64213 0.000353
10 4 2.5 778.28010
-
477.29770 0.144426
10 10 1 1278.5172 777.73315
-
0.070326
10 20 0.5 163.21670 1277.8990 0.048378
500 4 20 1 20 238.4743O 162.24105 0.601357
20 4 5 388.76922 237.92347 0.231515
20 10 2 639.00745 388.41115 0.092186
20 20 1 639.00745 638.66540 0.053556
500 4 40 1 40 80 950154 80 043753 1132382
40 4 10 118.71210 118.23983 0.399423
40 10 4 194.01081
-
193.75194 0.133607
40 20 2 319.25118 319.04873 0.063454Table 7.5 Comparison of AUC at different Ka and clearance ratios (VmIKm) of drug forone-compartment Michaelis-Menten system
with first-order input at the dose of 1000mg.
Dose
(mg)
Ka
(hf')
Vm
(mg/br)
Km
(mgIL)
VmIKm
(L/br)
AUC (equation 10)
(mg'hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
1000 0.3 5 1 5 2395.9584 2367.7032 1.193358
5 4 1.25 3000.1417 2982.3200 0.597578
5 10 0.5 4206.1514 4196.1200 0.239063
5 20 0.25 6212.3473 6206.6408 0.091941
1000 0.3 10 1 10 1179.2907 1152.0877 2.361192
10 4 2.5 1483.6048 2080.6971 1.143845
10 10 1 2089.77.37 3091.3049 0.436232
10 20 0.5 3096.0987 --
544.48440 0.155073
1000 0.3 20 1 20 570.00165 709.40795 4.686491
20 4 5 724.59637 1023.2798 2.140998
20 10 2 1031.1034 1533.8339 0.764568
20 20 1 1537.6991 241.20179 0.251998
1000 0.3 40 1 40 263.20190 331.44699 9.121039
40 4 10 343.44699 495.19403 3.620486
40 10 4 500.71990
-
755.50208 1.115898
40 20 2 757.91211 755.50208 0.318997
t.1,Table 7.5 (Continued)
Dose
(mg)
Ka
(br')
Vm
(mg/br)
Km
(mg/L)
Vm!Km
-
(L/hr)
AUC (equation 10)
(mg'hr/L)
AUC (trapezoidal)
(mg'br/L)
%difference in AUC
estimation
1000 0.75 5 1 5 2417.8085 2405.7634 0.500676
5 4 1.25 3019.4515 3011.5172 0.263465
5 10 0.5 4221.8184 4216.8917 0.116831
5 20 0.25 6224.2665 6220.8642 0.05469 1
1000 0.75 10 1 10 1201.6444 1190.1324 0.967286
10 4 2.5 1503.3075 1495.9522 0.491681
10 10 1 2105.6990 2101.4331 0.202997
10 20 0.5 3108.1672 3105.5796 0.083320
1000 0.75 20 1 20 593.41979 582.34651 1.901493
20 4 5 745.12419 738.21906 0.935376
20 10 2 1047.5660 1043.7494 0.365653
20 20 1 1550.0751 1547.9683 0.136099
1000 0.75 40 1 40 289.80052 278.51601 3.767698
40 4 10 365.80052
-
359.45450 1.765457
40 10 4 518.34795 515.00063 0.649965
40 20 2 770.94208 769.22581 0.223116Table 7.5 (Continued)
Dose
(mg)
Ka
(br')
Vm
(mg/br)
Km
(mg/L)
Vm!Km
(L/hr)
AUC (equation 10)
(mghr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
1000 1 5 1 5 2421.4093 2412.1444 0.384093
5 4 1.25 3022.6379 3016.4305 0.205784
5 10 0.5 4224.4084 4220.4075 0.094798
5 20 0.25 6226.2408 6223 .2975 0.047294
1000 1 10 1 10 1205.2860 1196.5051 0.733876
10 4 2.5 1506.5258 1500.8516 0.378061
10 10 1 2108.3101 2104.9360 0.160295
10 20 0.5 3110.1537 3108.0039 0.069169
1000 1 20 1 20 597.14508 588.70186 1.434209
20 4 5 748.40776 743.08986 0.715647
20 10 2 1050.2200-
1047.2258 0.285919
20 20 1 1552.0865 1550.3744 0.110430
1000 1 40 1 40 292.91045 284.83388 2.835538
40 4 10 369.22088 364.26489 1.360544
40 10 4 521.09121 518.42247 0.514780
40 20 2 773.00454 771.59488 0.182693Table 7.5 (Continued)
Dose
(mg)
Ka
(br')
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
1000 2 5 1 5 2426.7889 2421.7406 0.208459360
5 4 1.25 3027.4004 3023.8306 0.118055
5 10 0.5 4228.2823 4225.7163 0.060724
5 20 0.25 6229.1957 6226.9891 0.035436
1000 2 10 1 10 1210.7046 1206.0833 0.383 165
10 4 2.5 1511.3189 1508.2272 0.204992
10 10 1 2112.2042 2110.2184 0.094105
10 20 0.5 3113.1204
-
3111.6685 0.046658
1000 2 20 1 20 602.64302 598.25866 0.046658
20 4 5 753.26291 750.43257 0.377161
20 10 2 1054.1550 1052.4759 0.159544
20 20 1 1555.0768 1554.0123 0.068503
1000 2 40 1 40 298.57254 294.35378 1.433228
40 4 10 374.20388 371.54851 0.714675
40 10 4 525.11004 523.61736 0.285071
40 20 2 776.04325 775.19274 0.109715
00Table 7.5 (Continued)
Dose
(mg)
Ka
(hf1)
Vm
(mg/br)
Km
(mg/L)
Vm/Km
(L/hr)
AUC (equation 10)
(mg.br/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
1000 4 5 1 5 2429.4691 2426.5081 0.122027
5 4 1.25 3029.7741 3027.4973 0.075206
5 10 0.5 4230.2142 4228.3257 0.044662
5 20 0.25 62306702 6228.7777 0.030383
1000 4 10 1 10 1213.3944 1210.8601 0.209299
10 4 2.5 1513.7002 1511.9032 0.118854
10 10 1 211.4.1411 2112.8432 0.061428
10 20 0.5 3114.5978 3113.4756 0.036043
1000 4 20 1 20 605.35233 603.03708 0.383931
20 4 5 755.65947 754.10832 0.205693
20 10 2 1056.1021 1055.1023 0.094757
20 20 1 1556.5602 1555.8253 0.047235
1000 4 40 1 40 301.32151 299.12680 0.733703
40 4 10 376.63145 375.21314 0.378002
40 10 4 527.07753 526.23498 0.160109
40 20 2 777.53844 -
777.00201 0.069038Table 7.6 Comparison of AUC at different Ka and clearance ratios (VmiKm) of drug forone-compartment Michaelis-Menten system
with first-order input at the dose of 2500mg.
Dose
(mg)
Ka
(hr)
Vm
(mg/hr)
Km
(mgIL)
Vm/Km
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
2500 0.3 5 1 5 14358.921 14276.588 0.576700
5 4 1.25 15863.564 15798.970 0.408850
5 10 0.5 18871.572 18825.705 0.243637
5 20 0.25 23882.087 23851.373 0.128774
2500 0 3 10 1 10 7132 8641 7052 1533 1144497
10 4 2.5 7887.5678 1824.9969 0.799629
10 10 1 9395.6723 9351.4764 0.472608
10 20 0.5 11906.300 11877.317 0.244018
2500 0.3 20 1 20 3518.8965 3439.9569 2.294786
20 4 5 3898.7234 3837.8619 1.585817
20 10 2 4657.0262--
4614.7579 0.9 15937
20 20 1 5917.8849 5890.7664 0.460356
2500 0.3 40 1 40 1709.9410 1634.1495 4.637981
40 4 10 1902.5312 1844.9213 3.122622
40 10 4 2286.2532 2247.0195 1.746034
40 20 2 2922.5963-
2897.9661 0.849913Table 7.6 (Continued)
Dose
(mg)
Ka
(hf')
Vm
(mg/hr)
Km
(mgIL)
Vm/Km
(L/hr)
AUC (equation 10)
(mghr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
2500 0.75 5 1 5 14414.249 14380.126 0.237288
5 4 1.25 15916.092 15888.885 0.171228
5 10 0.5 18919.272 18899.545 0.104377
5 20 0.25 23923.452 23909.612 0.104377
2500 0.75 10 1 10 7188.7064-
7155.5951 0.057881
10 4 2.5 7940.5587 7914.7455 0.462733
10 10 1 9443.7542 9425.1078 0.326140
10 20 0.5 11947.951-
11935.343 0.197837
2500 0.75 20 1 20 3575.7887 3543.2626 0.105636
20 4 5 3952.6601 3927.3317 0.917969
20 10 2 4705.8863 4688.0235 0.644926
20 20 1 5960.1195 5948.4271 0.381031
2500 0.75 40 1 40 1769.0318 1737.1909 0.196562
40 4 10 1958.4424 1933.8221 1.832894
40 10 4 2336.7314 2319.5535 0.740569
40 20 2 2966.0377 2954.9203 0.376232
LITable 7.6 (Continued)
Dose
(mg)
Ka
(hf')
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mghr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
2500 1 5 1 5 14423.428 14397.252 0.181808
5 4 1.25 15924.808 15903.739 0.132475
5 10 0.5 18927.191 18911.709 0.081862
5 20 0.25 23930.322 23919.152 0.046697
2500 1 10 1 10 7197.9277 7172.7775 0.350634
10 4 2.5 7949.3133 7929.6537 0.247925
10 10 1 9451.7042 9437.6291 0.149138
10 20 0.5 11954.845-
11945.294 0.079959
2500 1 20 1 20 355.09549 3560.4664 0.691736
20 4 5 3961.4918 3942.2513 0.488057
20 10 2 4713.8999 4700.2524 0.290356
20 20 1 5967.0613 5958.0484 0.15 1272
2500 1 40 1 40 1778.5132 1754.4014 1.374360
40 4 10 1967.4314 1948.7147 0.960463
40 10 4 2344.8745 2331.7435 0.563137
40 20 2 2973.0766 2964.5063 0.289095Table 7.6 (Continued)
Dose
(mg)
Ka
(hr)
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg.br/L)
%difference in AUC
estimation
2500 2 5 1 5 14437.174 14423.060 0.097646
5 4 1.25 15937.862 15926.180 0.073352
5 10 0.5 18939.052 18930.132 0.047119
5 20 0.25 23940.615 23933.665 0.029037
2500 2 10 1 10 721.71415 7198.6290 0.181771
10 4 2.5 7962.4043 7952.1040 0.129528
10 10 1 9463.5955 9456.0600 0.079688
2500 2
10
20
20
1
0.5
20
11965.161 --
3598.9638
11959.818
3586.3185
0.044672
0.352597
20 4 5 3974.6566
13964.6916 0.251343
20 10 2 4725.8521 4718.6678 0.152251
20 20 1 5977.54775972.5585 0.081442
2500 2 40 1 40 1792.5477 1780.2285 0.692000
40 4 10 1980.7459 1971.1190 0.488397
40 10 4 2356.9599 2350.1104 0.291029
40 20 2 2983.5306 2978.9696 0.153107Table 7.6 (Continued)
Dose
(mg)
Ka
(hr')
Vm
(mg/hr)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
2500 4 5 1 5 14444.036 14436.045 0.055357
5 4 1.25 15944.380 15937.443 0.043529
5 10 0.5 18944.974 18939.390 0.029484
5 20 0.25 23945.755 23940.975 0.019967
2500 4 10 1 10 7968.9314 7211.5729 0.097262
10 4 2.5 9469.5260 7963.3539 0.700390
10 10 1 11970.307 9465.3040 0.044604
10 20
-
0.5 3605.8570 11967.112 0.026700
2500 4 20 1 20 3981.2021 3599.2552 0.183421
20 4 5 4731.7977 3975.9317 0.132558
20 10 2 5982.5805 4727.8997 0.082446
20 20 1 5982.5805 5979.8394 0.045839
2500 4 40 1 40 1799.4819 1793.1574 0.352700
40 4 10 1987.3283 1982.3464 0.251310
40 10 4 2362.9260 2359.3262 0.152576
40 20 2 2988.7113 2986.2342 0.082952Table 7.7 Comparison of AUC at different Ka and clearance ratios (Vm/Km) of drug forone-compartment Michaelis-Menten system
with first-order input at the dose of 5000mg.
Dose
(mg)
Ka
(hf')
Vm
(mg/hr)
Km
(mg/L)
Vm/Km
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
5000 0.3 5 1 5 56618.600 56444.129 0.309103
5 4 1.25 59623.415 59473.125 0.252703
5 10 0.5 65632.331 65510.569 0.185867
5 20 0.25 75645.380 75552.561 0.122852
5000 0.3 10 1 10 28216.199 28043.557 0.615619
10 4 2.5 29721.046 29572.736 0.501510
10 10 1 32730.019 32611.165 0.364455
10 20 0.5 37743.144 37653.384 0.238386
5000 0.3 20 1 20 14014.063 13843.779 1.230042
20 4
-
5 14768.975 14623.108 0.997510
20 10 2 16278.062--
16161.708 0.719931
20 20 1 18791.344--
18704.085 0.466523
5000 0.3 40 1 40 6911.0815 6744.0141 2.477268
40 4 10 7291.1253--
7148.6171 1.993507
40 10 4 8050.4477 7937.4881 1.423115
40 20 2 9314.0524 9230.0462 0.910138
(JTable 7.7 (Continued)
Dose
(mg)
Ka
(br1)
Vm
(mg/br)
Km
(mg/L)
VmlKm
(L/hr)
AUC (equation 10) AUC (trapezoidal)
(mg.hr/L) (mg.hr/L)
%difference in AUC
estimation
5000 0.75 5 1 5 56729.729 56657.934 0.126716
5 4 1.25 59731.648
-
59669.417 0.104293
5 10 0.5 65735.201 65683.767 0.078305
5 20 0.25 75740.402 75700.340 0.052921
5000 0.75 10 1 10 28327.846 28257.289 0.249695
10 4 2.5 29829.769 29768.900 0.204472
10 10 1 32833.331 32784.181 0.149921
10 20 0.5 37838.545 37800.947 0.099463
5000 0.75 20 1 20 14126.756 14057.419 0.493244
20 4 5 14878.690 14819.074 0.402296
20 10 2 16382.270 16334.425 0.292912
20 20 1 18887.508 18851.290 0.192125
5000 0.75 40 1 40 7025.9144 6957.4978 0.983351
40 4 10 7402.8686 7344.2069 0.798748
40 10 4 8156.4850 8109.6237 0.577847
40 20 2 9411.7727 9376.5557 0.375586Table 7.7 (Continued)
Dose
(mg)
Ka
(hr')
Vm
(mg/hr)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)1
(mg.hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
5000 1 5 1 5 56748.208 56693.358 0.096748
5 4 1.25 59749.646 59701.920 0.079940
5 10 0.5 65752.309 -
65712.416 0.060708
5 20 0.25 75756.208 75724.422 0.041975
5000 1 10 1 10 28346.367 28292.810 0.189296
10 4 2.5 29847.808 29801.500 0.155389
10 10 1 32850.476 32812.925 0.114441
10 20 0.5 37854.382 37825.444 0.076503-
5000 1 20 1 20 14145.364 14092.984 0.371672
20 4 5 14896.811 14851.710 0.303673
20 10 2 16399.489-
16363.200 0.221773
20 20 1 18903.408 18875.818 0.146166
5000 1 40 1 40 7044.6963 6993.0763 0.738159
40 4 10 7421.1543 7376.8393 0.600731
40 10 4 8173.8528 9138.3797 0.435874
40 20 2 9427.7999 9401.0572 0.284464Table 7.7 (Continued)
Dose
(mg)
Ka
(hr')
Vm
(mg/br)
Km
(mg/L)
VrnlKm
(L/hr)
AUC (equation 10)
(mg.hrIL)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
5000 2 5 1 5 56775.903 56746.827 0.051238
5 4 1.25 59776.622 59751.026 0.042837
5 10 0.5 65777.952 65755.761 0.033747
5 20 0.25 75779.899 75761.732 0.023979
5000 2 10 1 10 28374.104 28346.258 0.098234
10 4 2.5 29874.823 29850.580 0.081214
10 10 1 32876.154 32856.235 0.060626
10 20 0.5 378778J0 37862.401 0.041471
5000 2 20 1 20 14173.183 14146.417 0.189211
20 4 5 14923.904-
14900.766 0.155277
20 10 2 16425.238 16406.478 0.114346
20 20 1 189273.19 18912.738
7046.4913
0.076418
0.371688 5000 2 40 1 40 7072.6823--
40 4 10 7448.4056 7425.8625 0.303575
40 10 4 8199.7447 8181.6083 0.221672
40 20 2 9451.7042 9437.9181 0.146071Table 7.7 (Continued)
Dose
(mg)
Ka
(br1)
Vm
(mg/hr)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 10)
(mg.hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
5000 4 5 1 5 56789.741 56773.659 0.028325
5 4 1.25 59790.099 59775.670 0.024138
5 10 0.5 65790.764 65777.529 0.020121
5 20 0.25 75791.738 75780.324 0.015647
5000 4 10 1 10 28387.951 28373.036 0.052567
10 4 2.5 29888.311 29875.168 0.043991
10 10 1 32888.976 32877.942 0.033558
10 20 0.5 37889.949 37880.937 0.023790
5000 4 20 1 20 14187.052 14173.168 0.097959
20 4 5 14937.411 14925.324 0.080987
20 10 2 16438.077 16428.151 0.060421
20 20 1 18939.052 18931.236 0.041282
5000 4 40 1 40 7086.5919 7073.2274 0.188945
40 4 10 7461.9521--
7450.3990 0.155067
40 10 4 8212.6192 8203.2560 0.114139
40 20
j
2 9463.5955 9456.3876 0.076221U
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Figure 7.8 Plot of% difference in AUC versus Vm and Km at three different doses (50,
1000, and 5000 mg) when Ka = 0.3hr1.161
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Figure 7.9 Plot of% difference in AUC versus Vm and Km at three different doses (50,
1000, and 5000 mg) when Ka = 1 hf'.0)U
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Figure 7.10 Plot of% difference in AUC versus Vm and Km at three different doses (50,
1000, and 5000 mg) when Ka = 4 hf'.240
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Figure 7.11 Effect of absorption rate constant on AUC (Vm = 20 mg/br, Km = 4 mgIL, V =
44.8 L, Dose = 500 mg).
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Figure 7.12 Simulated plasma concentration-time profiles for the two-compartment model
following IV bolus administration using equation (8) and (9) when Vm = 20 mglhr, Km =
4 mg/L,CLD= 28.7 L/hr, V = 25.6 L,VT= 19.2 L, R = 1, and D = 50, 100, 500, 1000,
2500, and 5000 mg.Table 7.8 Comparison of AUC at different doses and clearance ratios (Vm/Km) of drug fortwo-compartment Michaelis-Menten
system after IV bolus administration.
Dose
(mg)
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/br)
AUC (equation 13)
(mg.br/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
50 5 1 5 15.580357 15.668100 0.560015
4 1.25 45.580357 45.630121 0.109059
10 0.5 105.58035 105.96129 0.030840
20 0.25 205.58035 205.59465 0.006956
50 10 1 10 7.7901785 7.8779932 1.114682
4 2.5 22.790178 22.839896 0.217678
10 1 52.790178 52.814780 0.046581
20 0.5 102.79017 102.80314 0.012608
50 20 1 20 3.8950892 3.9826224 2.197878
4 5 11.395089 11.443963 0.427075
10 2 26.395089 26.420398 0.095794
20 1 51.395089 51.409259 0.027563
50 40 1 40 1.9475446 2.0330439 4.205484
4 10 5.6975446 5.7447506 0.821724
10 4 13.197544 13.222317 0.187357
20 2 25.697544 25.711384 0.053828Table 7.8 (Continued)
Dose
(mg)
Vm
(mg/hr)
Km
(mgIL)
VmIKm
(L/hr)
AUC (equation 13)
(mg'hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
50 50 1 50 1.5580357 1.6419682 5.111704
4 12.5 4.5580357 4.6044203 1.007392
10 5 10.558035 10.582546 0.231616
20 2.5 20.558035 20.571786 0.066844
100 5 1 5 42.321428 42.500609 0.421595
4 1.25 102.32142 102.46300 0.138176
10 0.5 222.32142 222.40910 0.039420
20 0.25 422.32142 422.37064 0.011651
100 10 1 10 21.160714 21.342078 0.849797
4 2.5 51.160714 51.304476 0.280214
10 1 111.16071 111.24746 0.077976
20 0.5 211.16071 211.21314 0.024821
100 20 1 20 10.580357 10.768698 1.721596
4 5 25.580357 25.723010 0.554575
10 2 55.580357 55.666389 0.154549
20 1 105.58035 105.63158 0.048494Table 7.8 (Continued)
Dose
(mg)
Vm
(mg/br)
Km
(mg/L)
Vm/Km
(L/hr)
AUC (equation 13)
(mg.hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
100 40 1 40 5.2901785 5.4815651 3.491458
4 10 12.790178 12.930462 1.084912
10 4 27.790178 27.874857 0.303784
20 2 52.790178 52.840795 0.095792
100 50 1 50 4.2321428 4.4254575 4.368242
4 12.5 10.232142 10.371168 1.340505
10 5 22.232142 22.316152 0.376451
20 2.5 42.232142 42.282492 0.119079
500 5 1 5 658.03571 658.56240 0.079975
4 1.25 958.03571 958.89825 0.089951
10 0.5 1558.0357 1558.9150 0.056405
20 0.25 2558.0357 2558.7744 0.028871
500 10 1 10 329.01785 329.55032 0.161574
4 2.5 479.01785 479.88135 0.179939
10 1 779.01785 779.89585 0.112578
20 0.5 1279.0178 1279.7434 0.056695Table 7.8 (Continued)
Dose
(mg)
Vm
(mg/br)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 13)
(mg.hr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
500 20 1 20 164.50892 165.05765 0.332443
4 5 239.50892 240.37785 0.361482
10 2 389.50892 390.38578 0.224613
20 1 639.50892 640.23247 0.113012
500 40 1 40 82.254464 82.836913 0.703127
4 10 119.75446 120.63567 0.730474
10 4 194.75446 195.63164 0.448382
10 4 319.75446 320.47464 0.224742
500 50 1 50 65.803571 66.403252 0.903089
4 12.5 95.803571 96.690819 0.917613
10 5 155.80357 -
156.68103 0.560034
20 2.5 255.80357 256.52251 0.280264
1000 5 1 5 2432.1428 2432.8559 0.029312
4 1.25 3032 1428
--
3033.5657 0.046903
10 0.5 4232.1428 4233.5657
-
0.042285
20 0.25 6232.1428 6233.9223 0.028545Table 7.8 (Continued)
Dose
(mg)
Vm
(mg/hr)
Km
(mg/L)
Vm!Km
(L/hr)
AUC (equation 13)
(mghr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
1000 10 1 10 1216.0714 1216.7903 0.059086
4 2.5 1516.0714 1517.4945 0.093780
10 1 2116.0714 2117.8507 0.084015
20 0.5 3116.0714 3117.8337 0.056524
1000 20 1 20 608.03571 608.77085 0.120758
4 5
-
758.03571 759.47036 0.188901
10 2 1058M357
--
1059.8165 0.168033
20 1 1558.0357 1559.7918
-
0.112590
1000 40 1 40 304.01785 304.79202 0.253998
4 10 379.01785 380.47360 0.382614
10 4 529.01785 530.80596 0.336866
10 4 77901785 780.77249 0.224730
1000 50 1 50 243.21428 244.00880 0.325611
4 12.5 303.24128 304.68175 0.481640
10 5 423.21428 425.00640 0.421667
20 2.5 623.21428 624.96879 0.280736Table 7.8 (Continued)
Dose
(mg)
Vm
(mg/hr)
Km
(mg/L)
VmIKm
(L/hr)
AUC (equation 13)
(mg.hrIL)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
2500 5 1 5 1.4450.892 14451.858 0.006684
4 1.25 15950.892 15953.200 0.014461
10 0.5 18950.892 18954.499 0.019028
20 0.25 23950.892 23952.962 0.008639
2500 10 1 10 7225.4464 7226.4244 0.013534
4 2.5 7975.4464 7977.7655 0.029070
10 1 9475.4464 9478.9886 0.037369
20 0.5 11975.446 11979.743 0.035870
2500 20 1 20 3612.7232 3613.7295 0.027847
4 5 3987.7232 3990.0630 0.058640
10 2 4737.7232 4741.2799 0.075016
20 1 5987.7232 5992.0272 0.071828
2500 40 1 40 1806.3616 1807.3981 0.057351
4 10 1993.8616 1996.2243 0.118363
10 4 2368.8616 2372.4333 0.150552
20 2 2993.8616 2998.1752 0.143875Table 7.8 (Continued)
Dose
(mg)
Vm
(mg/hr)
Km
(mg/L)
VniIKm
(L/hr)
AUC (equation 13)
(mg.hr/L)
AUC (trapezoidal)
(mg.hr/L)
%difference in AUC
estimation
2500 50 1 50 1445.0892 1446.1491 0.073286
4 12.5 1595.0892 1597.4700 0.149035
10 5 1895.0892
-
1898.6722 0.188707
20 2.5 2395.0892 2399.4064 0.179927
5000 5 1 5 56803.571 56804.943 0.002415
4 1.25 59803.571 59806.807 0.005410
10 0.5 65803.571 65808.420 0.007368
20 0.25 75803.571 75810.787 0.009518
5000 10 1 10 28401785 28403.221 0.005054
4 2.5 29901.785 29905.072 0.010991
10 1 32901.785 32907.165 0.016347
20 0.5 37901.785 37908.997 0.019023
5000 20 1 20 14200.892 14202.100 0M08503
4 5 14950.892 14953.986 0.020685
10 2 16450.892 16456.133 0.031848
20 1 18950.892 18958.032 0.037658Table 7.8 (Continued)
Dose
(mg)
Vm
(mg/br)
Km
(mg/L)
VmlKm
(L/hr)
AUC (equation 13)
(mghr/L)
AUC (trapezoidal)
(mghr/L)
%difference in AUC
estimation
5000 40 1 40 7100.4464 7101.7133 0.017840
4 10 7475.4464 7478.5827 0.041936
10 4 8225.4464 8230.7097 0.063946
20 2 9475.4464 9482.5721 0.075145
50 50 1 50 5680.3571 5681.6263 0.022338
4 12.5 5980.3571 5983.4978 0.052488
10 5 6580.3571
-
6585.6240 0.079975
20 2.5 7580.3571 7587.4885 0.093989Table 7.9 Comparison of AUC using equation (10), linear pharmacokinetics. and trapezoidal rule method for drugs following
one-compartment system with first-order absorption and Michaelis-Menten elimination kinetics at low dose and low Ka.
Dose
(mg)
Ka
(hr)
Vm
(mg/hr)
Km
(mg/L)
Cmax
(mg/L)
AUC (trapezoidal)
(mghr/L)
AUC (linear)
(mghr/L)
AUC (equation 10)
(mghrIL)
50 0.3 20 1 0.3884 3.15159 2.5000 0.589190
50 0.3 40 0.2458 1.44935 1.2500 4.361193
50 0.3 40 4 0.4941 5.41505 5.0000 4.727385
100 0.3 40 1 0.5572 3A0620 2.5000 -27.15375173
DISCUSSIONS AND CONCLUSION
In linear pharmacokinetics, clearance is dose independent, but it becomes
concentration and consequently dose dependent in pharmacokinetic systems with nonlinear
elimination. Therefore the AUC calculation based on linear pharrnacokinetics can
underestimate the AUC of drugs having capacity-limited elimination process. The degree
of saturation of Michaelis-Menten elimination kinetics depends upon the concentration
produced after drug administration. Drugs given intravenously usually produce higher
concentrations than administered orally drug except when the rate of absorption from the
given dose is very rapid.
For drugs obeying one-compartment open model when elimination is in a
nonlinear fashion after intravenous administration, the AUC equation can be derived as
shown in equation(7).The percentage of the differences in AUC estimation obtained
directly from equation(7)and trapezoidal rule method demonstrated in Table7.1is very
small and such error can be explained by the truncation error of the procedure. Also, the
results in Table7.1 verify that the mathematical expression of AUC for one-compartment
system after intravenous administration having Michaelis-Menten elimination kinetics
works for any values of dose, Vm, and Km.
For drugs following a one-compartment open model system with first-order input
and Michaelis-Menten elimination kinetics, the AUC equation cannot be derived. Al-
Ghazawi (1998) proposed a preliminary equation for AUC prediction for drugs following
nonlinear pharmacokinetic following this model and showed that this equation works well
when the rate of absorption is very fast. When the given dose is absorbed rapidly,
instantaneous input can be assumed as in the case of IV administration, thus equation(7)
can be used to approximate the maximum AUC obtained from that dose. The more rapidly
a given dose is absorbed, the more closely will the AUC approach that calculated by
equation(7).When the absorption rate is very slow, the maximum concentration produced
by the administered dose would be sufficiently lower than Km which will not saturate the
elimination process. Under the condition of low Ka with high clearance ratio, the behavior
of drugs tend to follow linear pharmacokinetics, thus AUC calculated based on linear
pharmacokinetics will give a better approximation when compared to that calculated from174
equation (10), as shown in Table 7.9.
For drugs obeying two-compartment open model eliminated in nonlinear fashion
from the central compartment after intravenous administration, there is no simple
mathematical expression for the AUC equation since the differential equation explaining
this model cannot be integrated. Equation (13) proposed by Cheng and Jusko (1989) gives
a very good prediction with the percentage of the differences in AUC estimation less than
one percent in most of the cases of dose, Vm, and Km. In the case of low dose (50 and 100
mg) with clearance ratio higher than 10, the percentage of the differences in AUC
estimation is greater than one but still in the range of one to five percent error.
Since the differential equations explaining one-compartment open model system
with first-order input and two-compartment open model system after IV administration
with nonlinear elimination kinetics cannot be solved, the proposed preliminary AUC
equations by AI-Ghazawi (1998) and Cheng and Jusko (1989) can only give an
approximation of AUC for drugs following these systems. Although these two equations
cannot be applied to all cases of dose, Ka. and clearance ratio, it is a step forward in
nonlinear pharmacokrnetics which is highly unexplored.
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CHAPTER 8
CONCLUSION
Oxytetracycline is a widely used broad spectrum antibiotic for the treatment of
various infections in veterinary medicine. According to the pharmacokinetic parameters
obtained, administering oxytetracycline 8 mg/kg intravenously every 12 hours and an
initial loading dose of 20 mg/kg and a maintenance dose of 10 mg/kg every 48 hours with
LA-TM formulation to alpacas will achieve a steady state trough concentration of 2.26 and
3.04 .tg/mL, respectively. These dosing schedules will allow plasma concentrations above
the MIC of 2 jig!mL for most microorganisms.
In order to maintain florfenicol plasma level greater than 0.25 jig/mL, the MR thr
most pathogenic bacteria, 8 mg/kg body weight of florfenicol should be given to alpacas
every 12 hours which will achieve a steady state trough concentration of 0.36 tg/rnL.
The pharmacokinetics of oxytetracychne and florfencol in alpacas were compared
to the results previously obtained in llamas. The disposition of oxytetracycline in these
two animals was significantly different whereas the disposition of florfenicol in llamas and
alpacas was similar.
The pharmacokinetics of clorsulon was investigated in llamas following oral
administration at a single dose of 14 mg/kg. The plasma concentrations of clorsulon
produced by this dose in llamas is lower than the values reported for the clorsulon
pharmacokinetic studies in sheep and goats following oral administration at a single dose
of 7 mg/kg. This suggests the entire dose of clorsulon is not absorbed in llamas.
The results of the theoretical study in chapter 7 showed that the proposed AUC
equations for drug following one-compartment system with first-order input and two-
compartment system after IV administration with nonlinear elimination kinetics has
limitations for use to predict the AUC of drugs following these models. The proposed
AUC equations will not give a good prediction for drugs with low dose, low Ka, and high
clearance ratio.176
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